US20140011995A1 - Process for Preparing Compound Having HIV Integrase Inhibitory Activity - Google Patents

Process for Preparing Compound Having HIV Integrase Inhibitory Activity Download PDF

Info

Publication number
US20140011995A1
US20140011995A1 US13/814,333 US201113814333A US2014011995A1 US 20140011995 A1 US20140011995 A1 US 20140011995A1 US 201113814333 A US201113814333 A US 201113814333A US 2014011995 A1 US2014011995 A1 US 2014011995A1
Authority
US
United States
Prior art keywords
substituent
formula
optionally substituted
compound shown
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/814,333
Inventor
Yukihito Sumino
Moriyasu Masui
Diasuke Yamada
Fumiya Ikarashi
Kazuya Okamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Assigned to SHINOGI & CO., LTD reassignment SHINOGI & CO., LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IKARASHI, FUMIYA, MASUI, MORIYASU, OKAMOTO, KAZUYA, SUMINO, YUKIHITO, YAMADA, DAISUKE
Publication of US20140011995A1 publication Critical patent/US20140011995A1/en
Priority to US15/709,716 priority Critical patent/US10125146B2/en
Priority to US15/709,701 priority patent/US10000508B2/en
Priority to US15/709,742 priority patent/US9969750B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a method of producing compounds having HIV integrase inhibitory activity, using a novel method of producing pyrone derivatives and pyridone derivatives.
  • Patent Document 1 describes compounds (I) and (II), which are useful as anti-HIV drugs and shown by formulae:
  • Patent Documents 2 to 6 describe the following reaction formula as an improved method of producing compound (I).
  • reaction processes for obtaining compound (I) include 16 or 11 steps, respectively, and are very long, the total yield is low, thus being inefficient, a high toxic and harmful reaction is used. an expensive reagent is used, an environmentally harmful reagent is used.
  • Non-Patent Documents 1 and 2 describe a method of producing pyrane-4-one and pyridine 4-one.
  • Patent Document 7 and Non-Patent Document 3 describe a method of producing enaminone derivatives.
  • a method of producing pyronediester and pyridonediester of the present invention is not described in these documents.
  • Patent Document 8 is an international patent application by the present applicant. Though this document describes the method of producing pyronediester and pyridonediester identical to the present invention, compounds having HIV-integrase inhibitory activity and anti-HIV drugs are not described therein.
  • An object of the present invention is to efficiently produce compounds useful as an anti-HIV drug having HIV-integrase inhibitory activity, which are shown by formula (Y1) or formula (Y2), a pharmaceutically acceptable salt thereof, or their solvate, by using a novel pyrone derivative and a pyridone derivative, a method of producing the same, and a method of using the same:
  • R x is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E.
  • Substituent E halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio optionally substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by
  • the prevent invention provides the following items, which relate to a production method shown by the following reaction formula:
  • R x is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E, and substitutent E is as defined below) comprising a step of:
  • R 1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R 1e) 3
  • R 1e s are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E
  • R 2d is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E
  • R 3d is hydrogen, lower alkyloxy optionally substituted by substituent E, —N(R 3e ) 2 , —OR 3e
  • Substituent E halogen, cyano, hydroxyl, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substitu
  • R 4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E
  • R 5d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO 2 —R 5e
  • R 5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E
  • Substituent E is as defined above
  • a method according to Item 1 comprising a step of:
  • a method according to Item 4 comprising a step of:
  • a method according to Item 3 or 5 comprising a step of:
  • Step B and Step C are continuously performed.
  • a method according to Item 8 comprising a step of:
  • a method according to Item 9 comprising a step of:
  • a method according to Item 10 comprising a step of:
  • Hal is a halogen atom
  • the present invention provides the following items as other embodiments.
  • R x is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E, and substituent E is as defined below
  • R 1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R 1e ) 3
  • R 1e s are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E
  • Red is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E
  • R 3d is hydrogen, lower alkyloxy optionally substituted by substituent E, —N(R 3e ) 2 , or —OR 3e , R 3e s are
  • Substituent E halogen, cyano, hytroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, helogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, csrbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbon
  • R 4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E
  • R 6d is hydrogen, halogen, lower alkyloxy substituted by substituent E, or —O—SO 2 —R 5e
  • R 5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E, and substituent E is as defined above
  • substituent E is as defined above
  • the present invention enables production of compound (Y1) and compound (Y2) useful as anti-HIV drugs having HIV integrase inhibitory activity in a short step as compared to conventional methods, so the compounds can be efficiently produced in a high yield.
  • the present invention has a number of advantages, that use of a reaction reagent with toxicity can be avoided, use of harmful reaction can be avoided, use of an expensive reaction reagent can be avoided, use of an environmentally harmful reagent and solvent can be avoided, and the like. Therefore, the present invention is useful for the industrial production of anti-HIV drugs.
  • the crystals of compound (U1), compound (U2), and compound (U3) according to the present invention have advantages such as high stability to heat, high stability to light, high purification effect to remove impurities, easy handling, and/or small hygroscopy, and therefore, can be efficiently produced by utilizing those advantages.
  • FIG. 1 is a powder X-ray diffraction pattern of compound 12B obtained in Step 1 of Example 12.
  • the ordinate represents peak intensity, and the abscissa represents a diffraction angle (2 ⁇ ).
  • FIG. 2 is a powder X-ray diffraction pattern of compound 15A obtained in Example 15A.
  • the ordinate represents peak intensity, and the abscissa represents a diffraction angle (2 ⁇ ).
  • FIG. 3 is a powder X-ray diffraction pattern of compound 15B obtained in Example 15B.
  • the ordinate represents peak intensity, and the abscissa represents a diffraction angle (2 ⁇ ).
  • halogen encompasses fluorine, chlorine, bromine, and iodine atoms.
  • lower alkyl encompasses linear or branched alkyl having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, further preferably 1 to 4 carbon atoms, most preferably 1 or 2 carbon atoms.
  • Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl.
  • lower alkyl examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and n-pentyl. Examples of more preferred embodiments thereof include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • lower alkenyl encompasses linear or branched alkenyl having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, further preferably 2 to 4 carbon atoms and having one or more double bonds at an arbitrary position.
  • the “lower alkenyl” encompasses vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, and the like.
  • Examples of preferred embodiments of “lower alkenyl” include vinyl, allyl, propenyl, isopropenyl, and butenyl. Examples of particularly preferred embodiments thereof include allyl.
  • lower allyl moieties of “lower alkyloxy”, “lower alkylcarbonyl”, “lower alkyloxycarbonyl”, “carbocyclyl lower alkyl”, “heterocyclyl lower alkyl”, “halogeno lower alkyl”, “carbocyclyl lower alkyloxy”, “heterocyclyl lower alkyloxy”, “halogeno lower alkyloxy”, “lower alkyloxy lower alkyl”, “lower alkyloxy lower alkyloxy”, “lower alkylamino”, “lower alkylcarbonylamino”, “lower alkylaminocarbonyl”, “lower alkylsulfonyl”, “lower alkylsulfonylamino”, “carbocyclyl lower alkylthio”, “heterocyclyl lower alkylthio”, “carbocyclyl lower alkylamino”, and “heterocyclyl lower alkylamino” are also the same as
  • halogeno lower alkyl and “halogeno lower alkyloxy” are also the same as the “halogen” described above.
  • the “lower alkyl” and the “lower alkyloxy” may be substituted by one halogen atom or more identical or different halogen atoms at their respective arbitrary positions on the alkyl groups.
  • Carbocyclyl means carbocyclyl having 3 to 20 carbon atoms, preferably 3 to 16 carbon atoms, more preferably 4 to 12 carbon atoms and encompasses cycloalkyl, cycloalkenyl, aryl, non-aromatic condensed carbocyclyl, and the like.
  • cycloalkyl means carbocyclyl having 3 to 16 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 4 to 8 carbon atoms and encompasses, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
  • cycloalkenyl encompasses a group having one or more double bonds at an arbitrary position in the ring of the cycloalkyl. Examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptynyl, cyclooctynyl, and cyclohexadienyl.
  • aryl encompasses phenyl, naphthyl, anthryl, phenanthryl, and the like. Particularly, phenyl is preferred.
  • non-aromatic condensed carbocyclyl encompasses a group in which two or more cyclic groups selected from the “cycloalkyl”, “cycloalkenyl”, and “aryl” described above are condensed. Examples thereof include indanyl, indenyl, tetrahydronaphthyl, fluorenyl, and adamantyl.
  • Carbocyclyl examples include cycloalkyl, aryl, and non-aromatic condensed carbocyclyl. Specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and phenyl.
  • carbocyclyl moieties of “carbocyclyl lower alkyl”, “carbocyclyl lower alkyloxy”, “carbocyclyl lower alkylthio”, “carbocyclyl lower alkylamino”, “carbocyclyloxy”, “carbocyclylcarbonyl”, and “carbocyclylaminocarbonyl” are also the same as the ‘carbocyclyl’ described above.
  • the “carbocyclyl lower alkyl” in particularly preferred embodiments is benzyl.
  • Examples of preferred embodiments of “carbocyclyl lower alkyloxy” include benzyloxy.
  • Examples of preferred embodiments of “carbocyclyl lower alkylthio” include benzylthio.
  • Examples of preferred embodiments of “carbocyclyl lower alkylamino” include benzylamino.
  • Examples of preferred embodiments of “carbocyclyloxy” include phenyloxy.
  • Examples of preferred embodiments of “carbocyclylcarbonyl” include phenylcarbonyl.
  • Examples of preferred embodiments of “carbocyclylaminocarbonyl” include phenylaminocarbonyl.
  • heterocyclyl encompasses heterocyclyl having, in the ring, one or more identical or different heteroatoms arbitrarily selected from O, S, and N, such as heteroaryl, none-aromatic heterocyclyl, bicyclic condensed heterocyclyl, and tricyclic condensed heterocyclyl.
  • heteroaryl examples include 5- to 6-membered aromatic cyclyl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, and thiadiazolyl.
  • aromatic cyclyl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazo
  • Examples of the “none-aromatic heterocyclyl” include dioxanyl, thiiranyl, oxiranyl, oxetanyl, oxathiolanyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydrofuryl, tetrahydropyranyl, dihydrothiazolyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydrooxazinyl, hexahydroazepinyl,
  • bicyclic condensed heterocyclyl examples include indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, thienopyridyl, thienopyrrolyl, thienopyrazolyl, thienopyrazinyl,
  • tricyclic condensed heterocyclyl examples include carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl, imidazoquinolyl, and tetrahydrocarbazolyl.
  • heterocyclyl examples include 5- to 6-membered heteroaryl or none-aromatic heterocyclyl, and tricyclic condensed heterocyclyl.
  • heterocyclyl moieties of “heterocyclyl lower alkyl”, “heterocyclyl lower alkyloxy”, “heterocyclyl lower alkylthio”, “heterocyclyl lower alkylamino”, “heterocyclyloxy”, “heterocyclylcarbonyl”, and “heterocyclylaminocarbonyl” are also the same as the “heterocyclyl” described above.
  • the “heterocyclyl lower alkyl” in particularly preferred embodiments is pyridylmethyl.
  • heterocyclyl lower alkyloxy examples include pyridylmethyloxy.
  • heterocyclyl lower alkylthio examples include pyridylmethylthio.
  • heterocyclyl lower alkylamino examples include pyridylmethylamino.
  • heterocyclyloxy examples include pyridyloxy.
  • heterocyclylcarbonyl examples include pyridylcarbonyl.
  • heterocyclylaminocarbonyl examples include pyridylaminocarbonyl.
  • Step B and Step C are continuously performed.
  • Step C is carried out without performing the isolation operation (e.g., crystallization and collection by filtration, and distillation), extraction operation, and column chromatography purification of the product of Step B.
  • Step B and Step C may be performed in the same or different reactors.
  • lower alkyl optionally substituted by substituent E means that “lower alkyl” is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent E. When the lower alkyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other. Examples thereof include methyl, fluoromethyl, trifluoromethyl, chlorodifluoromethyl, and
  • carbocyclyl optionally substituted by substituent E means that “carbocyclyl” is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent E. When the carbocyclyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other.
  • the “carbocyclyl optionally substituted by substituent E” encompasses, for example, fluorophenyl, difluorophenyl, and methoxyfluorophenyl.
  • carbocyclyl lower alkyl optionally substituted by substituent E means that “carbocyclyl” and/or “lower alkyl” is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent E. When the carbocyclyl and/or the lower alkyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other.
  • the “carbocyclyl lower alkyl optionally substituted by substituent E” encompasses, for example, 4-fluorobenzyl, 2,4-difluorobenzyl, 4-methoxy-2-fluorobenzyl, and 4-methoxyphenyldifluoromethyl.
  • lower alkyloxy optionally substituted by substituent E “carbocyclyl lower alkyloxy optionally substituted by substituent E”, “heterocyclyl lower alkyloxy optionally substituted by substituent E”, and “lower alkenyl optionally substituted by substituent E” are also defined similarly.
  • carbocyclyl optionally substituted by substituent F means that ‘carbocyclyl’ is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent F. When the carbocyclyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other.
  • the “carbocyclyl optionally substituted by substituent F” encompasses, for example, fluorophenyl, difluorophenyl, and methoxyfluorophenyl.
  • carbocyclyl lower alkyloxy optionally substituted by substituent F means that the ‘carbocyclyl’ moiety is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent F. When the carbocyclyl moiety is bonded to a plurality of substituents, these substituents may be the same as or different from each other.
  • the “carbocyclyl lower alkyloxy optionally substituted by substituent F” encompasses, for example, fluorobenzyloxy, difluorobenzyloxy, and methoxyfluorobenzyloxy.
  • amino protective group can be any general protective group for the amino group and exemplified by amino protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons).
  • the “amino protective group” is preferably a tert-butyloxycarbonyl or benzyloxycarbonyl group.
  • the “carboxyl protective group” can be any general protective group for the carboxyl group and exemplified by carboxyl protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). Preferred examples thereof include methyl, ethyl, tert-butyl, methoxymethyl, allyl, benzyl, and p-methoxybenzyl groups.
  • Examples of the “counter anion of ammonium cation” represented by X d include halogen ⁇ , CH 3 COO ⁇ , HCOO ⁇ , NO 3 ⁇ , BF 4 ⁇ , PF 6 ⁇ , HO ⁇ , Ph-SO 3 ⁇ , CH 3 -Ph-SO 3 ⁇ , CH 3 —SO 3 ⁇ , PO 4 3 ⁇ , SO 4 2 ⁇ and HSO 4 ⁇ .
  • the “counter anion of ammonium cation” is preferably halogen ⁇ , CH 3 COO ⁇ , NO 3 ⁇ , or SO 4 2 ⁇ .
  • the counter anion represents that each NH 4 + cation is in an uncharged state by the binding of two or three molecules thereof.
  • NH 4 + X d ⁇ include NH 4 + Cl ⁇ , NH 4 + CH 3 COO ⁇ , (NH 4 + ) 2 SO 4 2 ⁇ , and (NH 4 + ) 3 PO 4 3 ⁇ .
  • the “leaving group” refers to a substituent that is eliminated through nucleophilic reaction. Examples thereof include halogen, —O—SO 2 —CH 3 , —O—SO 2 —CF 3 , —O—SO 2 -Ph, and —O—SO 2 -Ph-CH 3 .
  • the “leaving group” is preferably halogen.
  • Ph represents a phenyl group.
  • Examples of the salt include basic salts or acidic salts.
  • Examples of the basic salts include: alkali metal salts such as sodium salt, potassium salt, and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; aliphatic amine salts such as trimethylamine salt, triethylamine salt, dicyclohexylamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, procaine salt, meglumine salt, diethanolamine salt, and ethylenediamine salt; aralkylamine salts such as N,N-dibenzylethylenediamine and benethamine salt;
  • heterocyclic aromatic amine salts such as pyridine salt, picoline salt, quinoline salt, and isoquinoline salt; quaternary ammonium salts such as tetramethylammonium salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammonium salt, methyltrioctylammonium salt, and tetrabutylammonium salt; and basic amino acid salts such as arginine salt and lysine salt.
  • the acidic salts include: inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, and perchlorate; organic acid salts such as acetate, propionate, lactate, maleate, fumarate, tartrate, malate, citrate, and ascorbate; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, and p-toluenesulfonate; and acidic amino acids such as aspartate and glutamate.
  • inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, and perchlorate
  • organic acid salts such as acetate, propionate, lactate, maleate, fumarate, tartrate, malate, citrate, and ascorbate
  • sulfonates such as methanesulfonate, iseth
  • the salt derived from the carboxyl or hydroxyl group is preferably a basic salt, more preferably an alkali metal salt.
  • Particularly preferred examples of the salt include sodium salt, lithium salt, and potassium salt.
  • the most preferred example of the salt includes sodium salt.
  • the salt derived from the amine site is preferably an acidic salt, more preferably an inorganic acid salt.
  • preferable salts include hydrochloride and sulfate.
  • This step is the step of reacting compound (X1) with compound (V1) to obtain a solution containing compound (X2), as shown below in the reaction formula.
  • solution means compound (X2) in a dissolved state and also encompasses compound (X2) in a suspension or slurry form in which the compound is dispersed without being completely dissolved. This holds true for the description below, and the “solution” according to the present specification encompasses suspension and slurry forms.
  • the compound (X1) may be a commercially available reagent or can be obtained by a method known in the art.
  • nucleophilic substitution reaction may be performed, if desired in the presence of a base, in a solvent supplemented with an alcohol reagent such as a lower alcohol optionally substituted by substituent E, a carbocyclyl lower alkyl alcohol optionally substituted by substituent E, a heterocyclyl lower alkyl alcohol optionally substituted by substituent E, or (R 1e ) 3 Si—OH to obtain compound (X1) wherein R 1d is lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R 1e ) 3 .
  • an alcohol reagent such as a lower alcohol optionally substituted by substituent E, a carbocyclyl lower alkyl alcohol optionally substituted by substituent E, a heterocyclyl lower alkyl alcohol optionally substituted by substituent E, or (R 1e ) 3 Si—OH to obtain
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R 1d include methoxy, ethoxy, isopropoxy, trichloromethoxy, and trifluoromethoxy. Methoxy is preferred.
  • Examples of the “carbocyclyl lower alkyloxy optionally substituted by substituent E” represented by R 1d include benzyloxy, phenethyloxy, 2,4-difluorobenzyloxy, and 4-methoxybenzyloxy. Benzyloxy is preferred.
  • heterocyclyl lower alkyloxy optionally substituted by substituent E examples include pyridylmethyloxy.
  • R 1d in preferred embodiments is hydrogen, chloro, bromo, methoxy, or benzyloxy.
  • R 1d is —OSi(R 1e ) 3
  • R 1e in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, or the like.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R 2d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R 2d include benzyl and 4-methoxybenzyl.
  • heterocyclyl lower alkyl optionally substituted by substituent E examples include pyridylmethyl.
  • R 2d in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, 4-methoxybenzyl, or the like.
  • the reaction solvent used in the nucleophilic substitution reaction for obtaining the compound (X1) is preferably an aprotic solvent.
  • examples thereof include acetonitrile, tetrahydrofuran, dioxane, diethyl ether, dichloromethane, chloroform, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, and mixed solvents thereof.
  • the base can be any base capable of deprotonating the alcohol reagent.
  • Examples thereof include n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, sodium ethoxide, sodium hydride, lithium diisopropylamide, and lithium bis(trimethylsilyl)amide.
  • the amount of the base is approximately 1.0 to 3.0 molar equivalents with respect to compound (X1) wherein R 1d is halogen.
  • the amount of the alcohol reagent is approximately 0.5 to 1.5 molar equivalents with respect to compound (X1) wherein R 1d is halogen.
  • the reaction temperature is usually 0° C. to reflux temperature, preferably room temperature to 50° C.
  • the reaction time is usually 10 minutes to 50 hours, preferably 1 to 4 hours.
  • the compound (V1) can be obtained as a commercially available reagent or by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by P d include methyl, ethyl, and trifluoromethyl. P d in preferred embodiments is methyl.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R 3d include methoxy and ethoxy.
  • R 3d is —N(R 3e ) 2
  • examples of the “lower alkyl optionally substituted by substituent E” represented by R 3 ′ include methyl, ethyl, and trifluoromethyl.
  • R 3d in preferred embodiments is —N(CH 3 ) 2 , —OCH 3 , or pyrrolidinyl.
  • solvent of the reaction examples include acetonitrile, tetrahydrofuran, dioxane, diethyl ether, dichloromethane, chloroform, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, and mixed solvents thereof.
  • the amount of the compound (V1) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (X1), or the compound (V1) may be used as a solvent.
  • the reaction temperature is usually 0° C. to reflux temperature, preferably room temperature.
  • the reaction time is usually 30 minutes to 50 hours, preferably 2 to 8 hours.
  • the compound (X2) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • Compound (X2) may be obtained through the following reaction:
  • R 5d is halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO 2 —R 5e ′; and each of the other symbols is as defined above).
  • the compound (Z1) may be a commercially available reagent or can be obtained by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R 2d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R 2d include benzyl and 4-methoxybenzyl.
  • heterocyclyl lower alkyl optionally substituted by substituent E examples include pyridylmethyl.
  • R 2d in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, 4-methoxybenzyl, or the like.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by le d include methoxy and ethoxy.
  • R 3d is —N(R 3e ) 2
  • examples of the “lower alkyl optionally substituted by substituent E” represented by R 3e include methyl, ethyl, and trifluoromethyl.
  • R 3d in preferred embodiments is —N(CH 3 ) 2 , —OCH 3 , or pyrrolidinyl.
  • the compound (Z2) may be a commercially available reagent or can be obtained by a method known in the art.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R 1d include methoxy, ethoxy, isopropoxy, trichloromethoxy, and trifluoromethoxy. Methoxy is preferred.
  • Examples of the “carbocyclyl lower alkyloxy optionally substituted by substituent E” represented by R 1d include benzyloxy, phenethyloxy, 2,4-trifluorobenzyloxy, and 4-methoxybenzyloxy. Benzyloxy is preferred.
  • heterocyclyl lower alkyloxy optionally substituted by substituent E examples include pyridylmethyloxy.
  • R 1d in preferred embodiments is hydrogen, chloro, bromo, methoxy, or benzyloxy.
  • R 5d examples include chloro, bromo, methoxy, ethoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy.
  • solvent of the reaction examples include acetonitrile, tetrahydrofuran, dioxane, diethyl ether, dichloromethane, chloroform, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, and mixed solvents thereof.
  • the amount of the compound (Z2) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (Z1).
  • the reaction temperature is usually ⁇ 10° C. to reflux temperature, preferably room temperature.
  • the reaction time is usually 10 minutes to 10 hours, preferably 1 to 4 hours.
  • Tertiary amine is added, if necessary.
  • examples of the tertiary amine include pyridine, triethylamine, dimethylaminopyridine, and N-methylmorpholine.
  • the compound (X2) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • This step is the step of reacting compound (X2) with compound (V2), if desired in the presence of a base, to obtain a solution containing compound (X3) or a salt thereof, as shown below in the reaction formula:
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R 1d include methoxy, ethoxy, isopropoxy, trichloromethoxy, and trifluoromethoxy. Methoxy is preferred.
  • Examples of the “carbocyclyl lower alkyloxy optionally substituted by substituent E” represented by R 1d include benzyloxy, phenethyloxy, 2,4-trifluorobenzyloxy, and 4-methoxybenzyloxy. Benzyloxy is preferred.
  • heterocyclyl lower alkyloxy optionally substituted by substituent E examples include pyridylmethyloxy.
  • R 1d in Preferred embodiments is hydrogen, chloro, bromo, methoxy, or benzyloxy.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R 2d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R 2d include benzyl and 4-methoxybenzyl.
  • heterocyclyl lower alkyl optionally substituted by substituent E examples include pyridylmethyl.
  • R 2d in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, 4-methoxybenzyl, or the like.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R 3d include methoxy and ethoxy.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R 3e include methyl, ethyl, and trifluoromethyl.
  • R 3d in preferred embodiments is —N(CH 3 ) 2 , —OCH 3 , or pyrrolidinyl.
  • the compound (V2) can be obtained as a commercially available reagent or by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R 4d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R 4d include benzyl and 4-methoxybenzyl.
  • heterocyclyl lower alkyl optionally substituted by substituent E examples include pyridylmethyl.
  • R 4d examples include methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, and 4-methoxybenzyl. Particularly, methyl or ethyl is preferred.
  • R 5d examples include chloro, bromo, methoxy, ethoxy, acetoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. Particularly, chloro, methoxy, or ethoxy is preferred.
  • reaction solvent examples include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the base include n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, sodium ethoxide, sodium hydride, lithium diisopropylamide, and lithium bis(trimethylsilyl)amide.
  • the amount of the base used is approximately 1.0 to 5.0 molar equivalents with respect to compound (X2).
  • the amount of the compound (V2) used is approximately 1.5 to 5.0 molar equivalents with respect to compound (X2), or the compound (V2) may be used as a solvent.
  • the reaction temperature is usually ⁇ 80° C. to reflux temperature, preferably ⁇ 20° C. to 50° C.
  • the reaction time is usually 30 minutes to 50 hours, preferably 2 to 12 hours.
  • the compound (X3) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • the compound (X3) is isolated as crystals free from impurities by crystallization.
  • This step is the step of reacting compound (X2) with compound (V2) and compound (V2′), if desired in the presence of a base, to obtain compound (X4′) or a salt thereof as shown below in the reaction formula:
  • R 1d , R 2d , R 3d , R 4d and R 5d in the formulae (X2) and (V2) are the same as above.
  • reaction solvent examples include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the base include n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, sodium ethoxide, sodium hydride, lithium diisopropylamide, and lithium bis(trimethylsilyl)amide.
  • the amount of the base used is approximately 1.0 to 5.0 molar equivalents with respect to compound (X2).
  • the amount of the compound (V2) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (X2), or the compound (V2) may be used as a solvent.
  • the reaction temperature is usually ⁇ 80° C. to reflux temperature, preferably ⁇ 20° C. to 30° C.
  • the reaction time is usually 10 minutes to 10 hours, preferably 30 minutes to 4 hours.
  • Examples of the compound (V2′) include ammonium acetate, ammonium chloride, ammonium bromide, ammonium sulfate, ammonium bisulfate, ammonium formate, ammonium nitrate, ammonium hydroxide, ammonium phosphate, NH 4 + BF 4 ⁇ , NH 4 PF 6 ⁇ , NH 4 +Ph-SO 3 ⁇ , NH 4 + CH 3 -Ph-SO 3 ⁇ , and NH 4 + CH 3 —SO 3 ⁇ .
  • the compound (V2′) is preferably ammonium acetate, ammonium chloride, ammonium sulfate, ammonium bisulfate, or ammonium formate. (In this context, Ph represents a phenyl group.)
  • the amount of the compound (V2′) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (X2).
  • the reaction temperature is usually 0° C. to reflux temperature, preferably 20° C. to 80° C.
  • the reaction time is usually 10 minutes to 10 hours, preferably 30 minutes to 4 hours.
  • the compound (X4′) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • the compound (X4′) is isolated as crystals free from impurities by crystallization.
  • This step is the step of reacting compound (X3) or a salt thereof with compound (V3) or a salt thereof to obtain cot/mound (X41 or a salt thereof as shown below in the reaction formula:
  • the compound (V3) can be obtained as a commercially available reagent or by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R 6d include HC( ⁇ O)—CH 2 —, CH(—OH) 2 —CH 2 —, CH 3 O—CH(—OH)—CH 2 —, dimethoxyethyl, diethoxyethyl, HO—CH 2 —CH(—OH)—CH 2 —,
  • Examples of the “lower alkenyl optionally substituted by substituent E” represented by R 6d include CH 2 ⁇ CH—CH 2 —.
  • reaction solvent examples include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, methanol, ethanol, isopropanol, and mixed solvents thereof.
  • the amount of the compound (V3) used is approximately 1.0 to 2.0 molar equivalents with respect to compound (X3).
  • the reaction temperature is usually 0° C. to reflux temperature, preferably 20° C. to 70° C.
  • the reaction time is usually 30 minutes to 50 hours, preferably 2 to 12 hours.
  • R 6d in the formed compound (X4) is not an aldehyde group or a group having an equivalent thereof, such as HC( ⁇ O)—CH 2 —, CH 3 O—CH(—OH)—CH 2 —, or CH(—OH) 2 —CH 2 —
  • this moiety can be converted to HC( ⁇ O)—CH 2 —, CH 3 O—CH(—OH)—CH 2 —, or CH(—OH) 2 —CH 2 —, which is an aldehyde group or a group having an equivalent thereof, by deprotection methods for protective groups in aldehyde groups described in Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons) or a method known in the art as described in International Publication No. WO 2006/116764 or 2006/088173.
  • R 6d in compound (X4) is, for example, dimethoxyethyl
  • this moiety can be converted to HC( ⁇ O)—CH 2 — by the addition of an acid to the solution containing compound (X4).
  • the acid is not particularly limited and is exemplified by hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, maleic acid, and oxalic acid.
  • the amount of the acid used is 2.0 to 10.0 molar equivalents with respect to compound (X4).
  • Acetic acid or formic acid may be used as a solvent and may be used as a mixture with any of the acids described above.
  • the reaction temperature is usually approximately 0° C. to 80° C., preferably 10° C. to 40° C.
  • the reaction time is usually 30 minutes to 50 hours, preferably 2 to 12 hours.
  • a compound with a deprotected amino group can also be obtained by deprotection methods for protective groups in amino groups described in Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons) or a method known in the art. The order of deprotection reactions can be changed appropriately.
  • R 6d is an amino protective group
  • the amino protective group in compound (X4) can be subjected to deprotection reaction, followed by reaction with compound (V3′) in the subsequent step, as in Step C′ shown below, to obtain the compound (X4) of interest.
  • the compound (X4) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • the compound (X4) is isolated as crystals free from impurities by crystallization.
  • This step is the step of reacting compound (X4′) or a salt thereof with compound (V3′), if desired in the presence of a base, to obtain compound (X4) or a salt thereof, as shown below in the reaction formula:
  • R 1d , R 2d , R 4d , and R 6d in the formulae (X4′) and (V3′) are the same as those described above in Step B′ and Step C.
  • Examples of the “leaving group” represented by L d include halogen, —O—SO 2 —CH 3 , —O—SO 2 —CF 3 , —O—SO 2 -Ph, and —O—SO 2 -Ph-CH 3 .
  • Halogen is preferred. (In this context, Ph represents a phenyl group.)
  • R 6d in the formed compound (X4) does not have an aldehyde group or an equivalent thereof, such as HC( ⁇ O)—CH 2 —, CH 3 O—CH(—OH)—CH 2 —, or CH(—OH) 2 —CH 2 —
  • the method of converting this moiety to the aldehyde group or the equivalent thereof is also the same as above.
  • reaction solvent examples include acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the base include potassium carbonate, cesium carbonate, sodium hydride, n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, triethylamine, 4-dimethylaminopyridine, diisopropylethylamine, and DBU (1,8-diazabicyclo[5.4.0]undec-7-ene).
  • the amount of the base used is approximately 1.0 to 5.0 molar equivalents with respect to compound (X4′).
  • the amount of the compound (V3′) used is approximately 1.0 to 4.0 molar equivalents with respect to compound (X4′), or the compound (V3′) may be used as a solvent.
  • the reaction temperature is usually 0° C. to reflux temperature, preferably 20° C. to 80° C.
  • the reaction time is usually 30 minutes to 24 hours, preferably 1 to 8 hours.
  • the compound (X4) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • the compound (X4) is isolated as crystals free from impurities by crystallization.
  • This step is the step of reacting compound (X4) or a salt thereof with compound (V5) or compound (V5′), if desired in the presence of an acid, to obtain compound (X5) or compound (X5′), or a salt thereof, as shown below in the reaction formula:
  • R 1d , R 2d and R 4d are as defined above; R 6d is an aldehyde group or an equivalent thereof, such as HC( ⁇ O)—CH 2 —, CH 3 O—CH(—OH)—CH 2 —, or CH(—OH) 2 —CH 2 —; and when R 6d is not the aldehyde or the equivalent thereof, the method described above in Step C is performed).
  • R 1d , R 2d , and R 4d in the formulae (X4), (X5), and (X5′) are the same as above.
  • the compound (V5) and the compound (V5′) are commercially available reagents.
  • reaction solvent examples include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the acid include acetic acid, trifluoroacetic acid, formic acid, and methanesulfonic acid.
  • the amount of the acid used is 0.5 to 3.0 molar equivalents with respect to compound (X4).
  • the amount of the compound (V5) or the compound (V5′) used is approximately 1.0 to 2.0 molar equivalents with respect to compound (X4), or the compound (V5) or the compound (V5′) may be used as a solvent.
  • an alcohol reagent may be added, if desired, to thereby improve the reaction rate.
  • the alcohol reagent is preferably methanol, ethanol, or isopropanol, particularly preferably methanol.
  • the reaction temperature is usually 20° C. to reflux temperature, preferably 60° C. to 80° C.
  • the reaction time is usually 30 minutes to 24 hours, preferably 1 to 8 hours.
  • the compound (X5) or the compound (X5′) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • the compound (X5) or the compound (X5′) is isolated as crystals free from impurities by crystallization.
  • This step is the step of reacting compound (X5) or compound (X5′), or a salt thereof with compound (V6) or a salt thereof to obtain compound (X6) or compound (X6′), as shown below in the reaction formula:
  • R 1d and R 2d are as defined above;
  • R X is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E).
  • Examples of the “carbocyclyl optionally substituted by substituent E” represented by R X include phenyl, 2,4-difluorophenyl, and cyclohexyl.
  • heterocyclyl optionally substituted by substituent E represented by R X
  • examples of the “heterocyclyl optionally substituted by substituent E” represented by R X include pyridyl, morpholinyl, and isoxazolyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R X include benzyl, 4-methoxybenzyl, and 2,4-difluorobenzyl.
  • heterocyclyl lower alkyl optionally substituted by substituent E examples include pyridylmethyl and isoxazolylmethyl.
  • substituent E for the “carbocyclyl optionally substituted by substituent E”, “heterocyclyl optionally substituted by substituent E”, “carbocyclyl lower alkyl optionally substituted by substituent E”, and “heterocyclyl lower alkyl optionally substituted by substituent E” represented by R X include halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulfonylamino.
  • More preferred examples thereof include halogen, cyano, hydroxy, carboxy, formyl, amino, lower alkyl, halogeno lower alkyl, and lower alkyloxy. Further preferred examples thereof include halogen, lower alkyl, and lower alkyloxy. Halogen is most preferred.
  • R X in preferred embodiments is “carbocyclyl lower alkyl optionally substituted by substituent E” or “heterocyclyl lower alkyl optionally substituted by substituent E”.
  • R X in more preferred embodiments is “carbocyclyl lower alkyl optionally substituted by substituent E”.
  • R X in further preferred embodiments is “carbocyclyl lower alkyl optionally substituted by halogen”.
  • R X in the most preferred embodiment is 2,4-difluorobenzyl.
  • R 1d is hydrogen
  • this moiety can be converted appropriately to halogen using a halogenating agent such as N-bromosuccinimide, N-chlorosuccinimide, or sulfuryl chloride.
  • R 1d can be selected appropriately according to the reactivity of the reaction substrate. The order of these reactions can be changed appropriately.
  • compound (X6) or compound (X6′) can be induced through general dehydration-condensation reaction (e.g., a method using a condensation agent, an acid chloride formation method, or an acid anhydride formation method) of the carboxyl group and compound (V6).
  • general dehydration-condensation reaction e.g., a method using a condensation agent, an acid chloride formation method, or an acid anhydride formation method
  • amide compound (X6) or compound (X6′) can be obtained through reaction at 0° C. to 60° C., preferably 10° C.
  • a dehydration-condensation agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, or WSC.
  • a dehydration-condensation agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylur
  • R 2d is not hydrogen
  • this moiety is converted to a carboxyl group through general deprotection reaction of the carboxyl protective group.
  • Compound (X6) or compound (X6′) can be induced through the same dehydration-condensation reaction as above of the formed carboxyl group and compound (V6).
  • the carboxyl protective group is exemplified by carboxyl protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). Preferred examples thereof include methyl, ethyl, tert-butyl, methoxymethyl, allyl, benzyl, and p-methoxybenzyl groups.
  • compound (X6) or compound (X6′) can also be induced through aminolysis reaction using compound (V6).
  • the compound (X6) or the compound (X6′) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
  • the compound (X6) or the compound (X6′) is isolated as crystals free from impurities by crystallization.
  • R 6d is an aldehyde group or an equivalent thereof such as HC( ⁇ O)—CH 2 —, CH 3 O—CH(—OH)—CH 2 —, or CH(—OH) 2 —CH 2 —; and when R 6d is not the aldehyde or the equivalent thereof, the method described above in Step C is performed).
  • This step is the step of reacting compound (X5) or compound (X4), or a salt thereof with compound (V6) or a salt thereof to obtain compound (X4′′).
  • R 1d , R 2d , R 4d , and R X are the same as above.
  • compound (X4′′) can be induced through general dehydration-condensation reaction (e.g., a method using a condensation agent, an acid chloride formation method, or an acid anhydride formation method) of the carboxyl group and compound (V6).
  • general dehydration-condensation reaction e.g., a method using a condensation agent, an acid chloride formation method, or an acid anhydride formation method
  • amide compound (X6) can be obtained through reaction at 0° C. to 60° C., preferably 10° C.
  • a dehydration-condensation agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, or WSC.
  • a dehydration-condensation agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylur
  • R 2d is not hydrogen
  • this moiety is converted to a carboxyl group through general deprotection reaction of the carboxyl protective group.
  • Compound (X4′′) can be induced through the same dehydration-condensation reaction as above of the formed carboxyl group and compound (V6).
  • the carboxyl protective group is exemplified by carboxyl protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). Preferred examples thereof include methyl, ethyl, tert-butyl, methoxymethyl, allyl, benzyl, and p-methoxybenzyl groups. A methyl group is particularly preferred.
  • compound (X4′′) can also be induced through aminolysis reaction of compound (V6).
  • This step is the step of reacting the compound (X4′) obtained in Step E′ with compound (V5) or compound (V5′), if desired in the presence of an acid, to obtain compound (X6) or compound (X6′), or a salt thereof.
  • This step is the step of obtaining compound (Y1) or compound (Y2), or a salt thereof from compound (X6) or compound (X6′), as shown below in the reaction formula:
  • R S examples and preferred embodiments of R S are as defined above.
  • R 1d is lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R 1e ) 3
  • this moiety can be converted to a hydroxy group through hydroxy deprotection reaction known in the art described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons).
  • R 1d when R 1d is methyloxy, this moiety can be converted to a hydroxy group using a reagent such as (CH 3 ) 3 —Si—I, BBr 3 , or BF 3 .Et 2 O.
  • a reagent such as (CH 3 ) 3 —Si—I, BBr 3 , or BF 3 .Et 2 O.
  • R 1d is benzyloxy
  • this moiety can be converted to a hydroxy group using Pd—C/H 2 gas, a Raney-Ni reagent, or the like.
  • R 1d is —OSi(CH 3 ) 3
  • this moiety can be converted to a hydroxy group using a tetramethylammonium fluoride reagent.
  • R 1d is halogen
  • this moiety can be converted to a hydroxy group by reaction with potassium trimethylsilanolate or lithium trimethylsilanolate and the subsequent addition of an aqueous solution of an inorganic acid.
  • Examples of other conditions for the conversion reaction of halogen to a hydroxy group also include use of sodium hydride/water (Bioorganic Medicinal Chemistry Letters, 17, 1713, 2007), potassium hydroxide/tris(dibenzylideneacetone)dipalladium (Pd 2 dba 3 )/di-tert-butylarylphosphine (Journal of the American Chemical Society, 128, 10694, 2006), potassium phosphate hydrate (K 3 PO 4 .H 2 O)/tris(dibenzylideneacetone)dipalladium (Pd 2 dba 3 )/tri-tert-butylphosphine (Tetrahedron Letters, 48, 473, 2007).
  • the halogen represented by R 1d in the starting material may be derivatized directly.
  • this approach requires a smaller number of reaction steps and may construct a more advantageous industrial production method, compared with the method involving alcohol protection and/or deprotection reactions.
  • R 1d When R 1d is hydrogen, this R 1d may be converted to halogen through reaction with a halogenating agent such as N-bromosuccinimide, N-chlorosuccinimide, or sulfuryl chloride, followed by reaction with potassium trimethylsilanolate or lithium trimethylsilanolate and the subsequent addition of an aqueous solution of an inorganic acid in the same way as above to induce a hydroxy group. Accordingly, R 1d can be selected appropriately from among these substituents according to the reactivity of the reaction substrate.
  • a halogenating agent such as N-bromosuccinimide, N-chlorosuccinimide, or sulfuryl chloride
  • the compound (Y1) or the compound (Y2) can be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.).
  • the compound (Y1) or the compound (Y2) can be converted to a salt by the desired method.
  • the salt is preferably a basic salt, more preferably an alkali metal salt such as sodium salt, potassium salt, or lithium. The most preferred example thereof includes sodium salt.
  • the salt of compound (Y1) or compound (Y2) can be deposited by dissolving the compound (Y1) or the compound (Y2) in an organic solvent or a mixed solution of an organic solvent and water and adding an aqueous alkali solution or an organic base to the solution, followed by stirring. This dissolution is performed by heating, if necessary. Also, the salt deposition is performed by cooling, if necessary.
  • ethanol methanol, isopropyl alcohol, acetone, acetonitrile, tetrahydrofuran, or dichloromethane may be used as the organic solvent.
  • the steps described above can be combined arbitrarily to obtain compound (Y1) or compound (Y2), or a salt thereof. Also, one or two or more chemical reactions well known by those skilled in the art may be combined appropriately before and/or after each step.
  • WSC N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
  • HATU O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
  • DBU 1,8-diazabicyclo[5.4.0]-7-undecene
  • NBS N-bromosuccinimide
  • a THF (3 ml) solution of benzyl alcohol (1.00 g, 9.25 mmol) was added to a THF (4 ml) suspension of sodium tert-pentoxide (2.55 g, 23.2 mmol) at room temperature in a nitrogen atmosphere, and the mixture was stirred at 40° C. for 2 hours.
  • This reaction solution was cooled in an ice bath, and a THF (3 ml) solution of compound 1A (1.53 g, 10.2 mmol) was added dropwise thereto at 0-10° C.
  • the reaction solution was stirred at room temperature for 2 hours, and 2 N hydrochloric acid (15 ml) was then added thereto, followed by extraction two times with ethyl acetate.
  • a DMI (3 ml) solution of benzyl alcohol (0.66 g, 6.1 mmol) was added to a DMI (4 ml) suspension of sodium tert-pentoxide (1.67 g, 15.2 mmol) at room temperature in a nitrogen atmosphere, and the mixture was stirred at 40° C. for 2 hours.
  • This reaction solution was cooled in an ice bath, and a DMI (3 ml) solution of compound 2A (1.10 g, 6.68 mmol) was added dropwise thereto at 0-10° C. The reaction solution was stirred at 0-5° C.
  • N,N-dimethylformamide dimethyl acetal (4.9 ml, 36.5 mmol) was added dropwise to compound 3A (5.0 g, 30.4 mmol) under cooling at 0° C.
  • 100 ml of ethyl acetate was added to the reaction solution, and the organic layer was washed with a 0.5 N aqueous hydrochloric acid solution (50 ml).
  • the aqueous layer was separated, followed by extraction with ethyl acetate (50 ml).
  • the organic layers were combined, washed with a saturated aqueous solution of sodium bicarbonate and saturated saline in this order, and then dried over anhydrous sodium sulfate.
  • Lithium hexamethyldisilazide (1.0 M solution in toluene, 49 ml, 49.0 mmol) was diluted with tetrahydrofuran (44 ml).
  • the mixture was stirred at ⁇ 78° C. for 2 hours and then heated to 0° C.
  • N,N-dimethylformamide dimethyl acetal (12.2 ml, 92.2 mmol) was added dropwise to compound 4A (10.0 g, 76.8 mmol) under cooling at 0° C. After stirring at 0° C. for 1.5 hours and then at room temperature for 2.5 hours, 100 ml of ethyl acetate was added to the reaction solution, and the solvent was distilled off. The obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 5:5 ⁇ 0:10 (v/v)) to obtain 12.45 g (yield: 88%) of compound 4B as an oil.
  • Lithium hexamethyldisilazide (1.0 M solution in toluene, 24 ml, 24.0 mmol) was diluted with tetrahydrofuran (20 ml).
  • a tetrahydrofuran (5 ml) solution of compound 4B (1.85 g, 10.0 mmol) was added dropwise thereto under cooling at ⁇ 78° C., and a tetrahydrofuran (5 ml) solution of ethyl oxalyl chloride (1.34 ml, 12.0 mmol) was then added dropwise thereto.
  • 2 N hydrochloric acid was added to the reaction solution, and the mixture was stirred at room temperature for 20 minutes.
  • N-bromosuccinimide (1.46 g, 8.18 mmol) was added to a N,N-dimethylformamide (10 ml) solution of compound 4D (2.68 g, 8.18 mmol), and the mixture was stirred at room temperature for 48 hours.
  • a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated saline in this order and then dried over anhydrous sodium sulfate.
  • Potassium trimethylsilanolate (249 mg, 1.95 mmol) was added to a 1,2-dimethoxyethane (3 ml) solution of compound 4G (300 mg, 0.78 mmol), and the mixture was stirred at room temperature for 1 hour. Potassium trimethylsilanolate (249 mg, 1.95 mmol) was further added thereto, and the mixture was stirred at 60° C. for additional 1 hour. 1 N hydrochloric acid and saturated saline were added to the reaction solution, followed by extraction with chloroform. The chloroform layers were combined and dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 100.3 mg (yield: 43%) of compound 3G as a yellow powder.
  • Lithium hexamethyldisilazide (1.0 M solution in toluene, 12 ml, 12.0 mmol) was diluted with tetrahydrofuran (11 ml).
  • a tetrahydrofuran (2 ml) solution of compound 6A (1.46 g, 5.0 mmol) was added dropwise thereto under cooling at ⁇ 78° C., and a tetrahydrofuran (2 ml) solution of ethyl oxalyl chloride (0.67 ml, 6.0 mmol) was then added dropwise thereto. After stirring at ⁇ 78° C.
  • Cesium carbonate (73.3 mg, 0.23 mmol) and bromoacetaldehyde dimethyl acetal (38.0 mg, 0.23 mmol) were added to a N,N-dimethylformamide (1 ml) solution of compound 6B (51.8 mg, 0.15 mmol), and the mixture was stirred overnight at room temperature.
  • Cesium carbonate (73.3 mg, 0.23 mmol) and bromoacetaldehyde dimethyl acetal (38.0 mg, 0.23 mmol) were further added thereto, and the mixture was stirred at 100° C. for additional 20 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate.
  • the acetal moiety of the compound 10B obtained in Example 10 is converted to an aldehyde group in the same way as in Step 4 of Example 3.
  • the resulting compound is reacted with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol.
  • the benzyl group which is an alcohol protective group, can be subjected to deprotection reaction (using, for example, Pd—C/H 2 gas) to induce the compound (Y1) or (Y2) of interest.
  • Example 11 The compound 11B obtained in Example 11 can be used in the next reaction in the same way as in Example 6.
  • the compound 12B was dried under conditions of concentration under reduced pressure and left standing at 5° C. for approximately 2 months. In this case, this compound was still in an oil form and was not crystallized. As a result of various studies, however, the compound was successfully crystallized by repeating the addition of ethyl acetate and concentration and isolated as white crystals.
  • the powder X-ray diffractometry of the crystals obtained in each Example was performed under the following measurement conditions according to the powder X-ray diffractometry described in the general test methods of the Japanese Pharmacopoeia.
  • the crude product A-2 obtained in the preceding step was dissolved in ethanol (40 ml). To the solution, a 2 N aqueous sodium hydroxide solution (20 ml) was added at room temperature, and the mixture was stirred at the same temperature for 2 hours. The reaction solution was neutralized to pH 7 using a 2 N aqueous hydrochloric acid solution. The solvent was directly distilled off. The obtained crude product A-3 was subjected to azeotropy with toluene (100 ml) and used in the next step without being purified.
  • the production method according to the present invention can reduce the number of steps for producing compounds having HIV integrase inhibitory activity from, for example, conventionally required 16 to 11 steps to preferably 8 to 6 steps.
  • the production method of the present invention is applicable as an efficient industrial production method and as such, has industrial applicability.

Abstract

A process for preparing a compound represented by formula (Y1) or (Y2) [wherein Rx is an optionally substituted carbocyclyl lower alkyl, or the like] or a salt thereof, using a novel process for preparing a pyridone derivative represented by formula (X4) [wherein R1d is hydrogen, halogen, or the like; R2d is hydrogen, a lower alkyl optionally substituted with substituent E, or the like; R4d is a lower alkyl optionally substituted with substituent E, or the like; and R6d is a lower alkyl group optionally substituted with substituent group E, or the like].

Description

    TECHNICAL FIELD
  • The present invention relates to a method of producing compounds having HIV integrase inhibitory activity, using a novel method of producing pyrone derivatives and pyridone derivatives.
    • BACKGROUND ART
  • Patent Document 1 describes compounds (I) and (II), which are useful as anti-HIV drugs and shown by formulae:
  • Figure US20140011995A1-20140109-C00001
  • This document describes the following reaction formula as a method of producing compound (I).
  • Figure US20140011995A1-20140109-C00002
    Figure US20140011995A1-20140109-C00003
  • Furthermore, Patent Documents 2 to 6 describe the following reaction formula as an improved method of producing compound (I).
  • Figure US20140011995A1-20140109-C00004
    Figure US20140011995A1-20140109-C00005
  • However, the above production methods of these documents are not satisfactory for the industrial manufacturing method because of the followings:
  • these reaction processes for obtaining compound (I) include 16 or 11 steps, respectively, and are very long,
    the total yield is low, thus being inefficient,
    a high toxic and harmful reaction is used.
    an expensive reagent is used,
    an environmentally harmful reagent is used.
  • Therefore, the development of a method for more efficient industrial mass-production of compound (I), compound (II) and their derivatives has been desired.
  • Non-Patent Documents 1 and 2 describe a method of producing pyrane-4-one and pyridine 4-one. Patent Document 7 and Non-Patent Document 3 describe a method of producing enaminone derivatives. However, a method of producing pyronediester and pyridonediester of the present invention is not described in these documents. Furthermore, a method of manufacturing compounds having HIV-integrase inhibitory activity by using the production method of the present invention is not disclosed. Patent Document 8 is an international patent application by the present applicant. Though this document describes the method of producing pyronediester and pyridonediester identical to the present invention, compounds having HIV-integrase inhibitory activity and anti-HIV drugs are not described therein.
    • PRIOR ART DOCUMENTS Patent Documents
    • [Patent Document 1] International publication No. 2006/116764 pamphlet
    • [Patent Document 2] International publication No. 2010/011812 pamphlet
    • [Patent Document 3] International publication No. 2010/011819 pamphlet
    • [Patent Document 4] International publication No. 2010/068262 pamphlet
    • [Patent Document 5] International publication No. 2010/067176 pamphlet
    • [Patent Document 6] International publication No. 2010/068253 pamphlet
    • [Patent Document 7] U.S. Pat. No. 4,769,380A
    • [Patent Document 8] International application PCT/JP2010/055316
    Non-Patent Documents
    • [Non-Patent Document 1] Journal of Organic Chemistry, 1991, 56(16), 4963-4967
    • [Non-Patent Document 2] Science of Synthesis, 2005, 15, 285-387
    • [Non-Patent Document 3] Journal of Chemical Society Parkin Transaction. 1, 1997, Issue. 2, 163-169
    SUMMARY OF THE INVENTION Problem to be Solved by the Invention
  • An object of the present invention is to efficiently produce compounds useful as an anti-HIV drug having HIV-integrase inhibitory activity, which are shown by formula (Y1) or formula (Y2), a pharmaceutically acceptable salt thereof, or their solvate, by using a novel pyrone derivative and a pyridone derivative, a method of producing the same, and a method of using the same:
  • Figure US20140011995A1-20140109-C00006
  • (wherein Rx is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E.
    Substituent E: halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio optionally substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substituent F, carbocyclylaminocarbonyl optionally substituted by substituent F, heterocyclylaminocarbonyl optionally substituted by substituent F, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulformyl, and lower alkylsulformylamino; Substituent F: halogen, hydroxy, carboxy, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, and amino protective group)
    • Means for Solving the Problems
  • The prevent invention provides the following items, which relate to a production method shown by the following reaction formula:
  • Figure US20140011995A1-20140109-C00007
    • (Item 1)
  • A method of producing a compound shown by formula (Y1) or formula (Y2) or a salt thereof:
  • Figure US20140011995A1-20140109-C00008
  • (wherein Rx is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E, and substitutent E is as defined below) comprising a step of:
    • (Step B)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00009
  • (wherein,
    R1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e) 3,
    R1es are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
    R2d is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
    R3d is hydrogen, lower alkyloxy optionally substituted by substituent E, —N(R3e)2, —OR3e,
    R3es are each independently lower alkyl optionally substituted by substituent E, or two R3es in —N(R3e)2 together with the adjacent nitrogen atom may form a heterocycle, and
    a wavy line means E form and/or Z form or a mixture thereof.
    Substituent E: halogen, cyano, hydroxyl, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substituent F, carbocyclylaminocarbonyl optionally substituted by substituent F, heterocyclylaminocarbonyl optionally substituted by substituent F, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxy carbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulformylamino;
    Substituent F: halogeno, hydroxyl, carboxy, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, and amino protecting group)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00010
  • (wherein,
    R4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
    R5d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO2—R5e,
    R5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E, and Substituent E is as defined above)
    to obtain a compound shown by formula (X3) or a salt thereof:
  • Figure US20140011995A1-20140109-C00011
  • (wherein each symbol is as defined above).
    • (Item 2)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00012
  • (wherein Rx is as defined in Item 1)
    comprising a step of:
    • (Step C)
  • reacting a compound shown by formula (X3), or a salt thereof:
  • Figure US20140011995A1-20140109-C00013
  • (wherein each symbol is as defined above).
    with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 12]

  • H2N—R6d  (V3)
  • (wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E, and substituent E is as defined in Item 1).
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00014
  • (wherein each symbol is as defined in Item 1 or above).
    • (Item 3)
  • A method of producing of a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00015
  • (wherein each symbol is as defined in Item 1)
    comprising a step of:
    • (Step D)
  • reacting a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00016
  • (wherein each symbol is as defined in Item 1 or Item 2) with (R)-3-amino-butan-1-ol, or (5)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′):
  • Figure US20140011995A1-20140109-C00017
  • (wherein each symbol is as defined in Item 1).
    • (Item 4)
  • A method according to Item 1 comprising a step of:
    • (Step C)
  • reacting a compound shown by formula (X3), or a salt thereof:
  • Figure US20140011995A1-20140109-C00018
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 18]

  • H2N—R6d  (V3)
  • (wherein R6d is as defined in Item 2)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00019
  • (wherein each symbol is as defined in Item 1 or Item 2).
    • (Item 5)
  • A method according to Item 4 comprising a step of:
    • (Step D)
  • reacting a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00020
  • (wherein each symbol is as defined in Item 1 or Item 2)
    with (R)-3-amino-butan-1-ol, or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00021
  • (wherein each symbol is as defined in Item 1).
    • (Item 6)
  • A method according to Item 3 or 5 comprising a step of:
    • (Step E)
  • reacting a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00022
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (V6), or a salt thereof:

  • [Chemical formula 23]

  • RX—NH2  (V6)
  • (wherein Rx is as defined in Item 1)
    to obtain a compound shown by formula (X6) or formula (X6′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00023
  • (wherein each symbol is as defined in Item 1).
    • (Item 7)
  • A method according to Item 4, 5 or 6, wherein Step B and Step C are continuously performed.
    • (Item 8)
  • A method of producing of a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00024
  • (wherein Rx is as defined in Item 1)
    comprising a step of:
    • (Step B′)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00025
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00026
  • (wherein each symbol is as defined in Item 1)
    and a compound shown by formula (V2′):

  • [Chemical formula 28]

  • NH4+Xd−  (V2′)
  • (wherein Xd− is a counter anion of ammonium cation)
    to obtain a compound shown by formula (X4′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00027
  • (wherein each symbol is as defined in Item 1).
    • (Item 9)
  • A method according to Item 8 comprising a step of:
    • (Step C′)
  • reacting a compound shown by formula (X4′):
  • Figure US20140011995A1-20140109-C00028
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (V3′):

  • [Chemical formula 31]

  • R6d-Ld  (V3′)
  • (wherein R6d is as defined in Item 2, Ld is a leaving group)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00029
  • (wherein each symbol is as defined in Item 1 or 2).
    • (Item 10)
  • A method according to Item 9 comprising a step of:
    • (Step D)
  • reacting a compound shown by formula (X4):
  • Figure US20140011995A1-20140109-C00030
  • (wherein each symbol is as defined in Item 1 or Item 2)
    with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00031
  • (wherein each symbol is as defined in Item 1).
    • (Item 11)
  • A method according to Item 10 comprising a step of:
    • (Step E)
  • reacting a compound shown by formula (X5) or formula (X5′):
  • Figure US20140011995A1-20140109-C00032
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (V6), or a salt thereof:

  • [Chemical formula 36]

  • RX—NH2  (V6)
  • (wherein Rx is as defined in Item 1)
    to obtain a compound shown by formula (X6) or formula (X6′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00033
  • (wherein each symbol is as defined in Item 1).
    • (Item 12)
  • A method according to Item 1, or any one of Items 4 to 11, wherein the compound shown by formula (X2) is obtained by reacting a compound shown by formula (X1):
  • Figure US20140011995A1-20140109-C00034
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (V1):
  • Figure US20140011995A1-20140109-C00035
  • (wherein Pd is lower alkyl optionally substituted by substituent E, and R3d and substituent E are as defined in Item 1).
    • (Item 13)
  • A method according to Item 1 or any one of Items 4 to 11, wherein the compound shown by formula (X2) is obtained by reacting a compound shown by formula (Z1):
  • Figure US20140011995A1-20140109-C00036
  • (wherein each symbol is as defined in Item 1)
    with a compound shown by formula (Z2):
  • Figure US20140011995A1-20140109-C00037
  • (wherein each symbol is as defined in Item 1).
    • (Item 14)
  • A method according to any one of Items 1 to 13, wherein Rx is carbocyclyl lower alkyl optionally substituted by substituent E.
    • (Item 15)
  • A method according to any one of Items 1 to 13, wherein Rx is 2,4-difluorobenzyl.
    • (Item 16)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00038
  • (wherein Rx is as defined in Item 1)
    comprising steps of:
    • (Step C″)
  • reacting a compound shown by formula (W1):
  • Figure US20140011995A1-20140109-C00039
  • with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 44]

  • H2N—R6d  (V3)
  • (wherein R6d is as defined in Item 2)
    to obtain a compound shown by formula (W2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00040
  • (wherein R6d is as defined in Item 2), and
    • (Step D″)
  • reacting a compound shown by formula (W2) with (R)-3-amino-burane-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (W3) or formula (W4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00041
  • , and
    • (Step F)
  • reacting a compound shown by formula (W3) or formula (W4) with a halogenating agent to obtain a compound shown by formula (W5) or formula (W6), or a salt thereof:
  • Figure US20140011995A1-20140109-C00042
  • (wherein Hal is a halogen atom).
    • (Item 17)
  • A crystal of a compound shown by formula (U1) or a solvate thereof:
  • Figure US20140011995A1-20140109-C00043
  • (wherein Me is methyl, and Bn is benzyl)
    which has peaks in a powder X-ray diffraction spectrum at diffraction angle (2θ): 11.2°±0.2°, 17.2°±0.2°, 17.7°±0.2°, 20.5°±0.2°, 22.0°±0.2° and 26.1°±0.2°.
    • (Item 18)
  • A crystal of a compound shown by formula (U2) or a solvate thereof:
  • Figure US20140011995A1-20140109-C00044
  • (wherein Me is methyl, and Bn is benzyl)
  • which has peaks in a powder X-ray diffraction spectrum at diffraction angle (20): 7.3°±0.2°, 14.4°±0.2°, 16.1°±0.2°, 18.4°±0.2°, 22.3°±0.2° and 23.1°±0.2°.
    • (Item 19)
  • A crystal of a compound shown by formula (U3) or a solvate thereof:
  • Figure US20140011995A1-20140109-C00045
  • (wherein Me is methyl, and Bn is benzyl)
    which has peaks in a powder X-ray diffraction spectrum at diffraction angle (2θ): 7.2°±0.2°, 16.1°±0.2°, 18.3°±0.2°, 20.6°±0.2°, 22.6°±0.2°, 23.1°±0.2° and 23.7°±0.2°.
    • (Item 20)
  • A crystal according to Item 17, which is characterized by a powder X-ray diffraction spectrum substantially consistent with FIG. 1.
    • (Item 21)
  • A crystal according to Item 18, which is characterized by a powder X-ray diffraction spectrum substantially consistent with FIG. 2.
    • (Item 22)
  • A crystal according to Item 19, which is characterized by a powder X-ray diffraction spectrum substantially consistent with FIG. 3.
  • The present invention provides the following items as other embodiments.
    • (Item I)
  • A method of producing a compound shown by formula (Y1) or formula (Y2) or a salt thereof:
  • Figure US20140011995A1-20140109-C00046
  • (wherein Rx is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E, and substituent E is as defined below)
  • comprising a step of reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00047
  • (wherein R1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e)3,
    R1es are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E, Red is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
    R3d is hydrogen, lower alkyloxy optionally substituted by substituent E, —N(R3e)2, or —OR3e ,
    R3es are each independently lower alkyl optionally substituted by substituent E, or two R3es in —N(R3e)2 together with the adjacent nitrogen atom may form a heterocycle, and the wavy line means E form and/or Z form or their mixture.
    Substituent E: halogen, cyano, hytroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, helogeno lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, csrbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substituent F, carbocycicylaminocarbonyl optionally substituted by substituent F, heterocyclylaminocarbonyl optionally substituted by substituent F, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower allyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulfonylamino;
    Substituent F: halogen, hydroxyl, carboxy, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower allyloxy, and amino protective group)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00048
  • (wherein R4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl substituted by substituent E,
    R6d is hydrogen, halogen, lower alkyloxy substituted by substituent E, or —O—SO2—R5e,
    R5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E, and substituent E is as defined above)
    to obtain a compound shown by formula (X3) or a salt thereof:
  • Figure US20140011995A1-20140109-C00049
  • (wherein each symbol is as defined above).
    • (Item II)
  • A method of producing a compound shown by formula (Y1) or formula (Y2) or a salt thereof:
  • Figure US20140011995A1-20140109-C00050
  • (wherein Rx is as defined in Item I)
    comprising a step of reacting a compound shown by formula (X3) or a salt thereof:
  • Figure US20140011995A1-20140109-C00051
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 57]

  • H2N—R6d  (V3)
  • (wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E, and substituent E is as defined in Item I)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00052
  • (wherein each symbol is as defined in Item I or above).
    • (Item III)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00053
  • (wherein Rx is as defined in Item I)
    comprising a step of reacting a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00054
  • (wherein each symbol is as defined in Item I or II)
    with (R)-3-amino-butan-1-01 or (5)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′):
  • Figure US20140011995A1-20140109-C00055
  • (wherein each symbol is as defined in Item I).
    • (Item IV)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00056
  • (wherein Rx is as defined in Item I)
    comprising steps of:
    • (Step B)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00057
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00058
  • (wherein each symbol is as defined in Item I)
    to obtain a compound shown by formula (X3) or a salt thereof:
  • Figure US20140011995A1-20140109-C00059
  • (wherein each symbol is as defined in Item I); and
    • (Step C)
  • reacting a compound shown by formula (X3) or a salt thereof with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 66]

  • H2N—R6d
  • (wherein R6d is as defined in Item II)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00060
  • (wherein each symbol is as defined in Item I or II).
    • (Item IV′)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00061
  • (wherein Rx is as defined in Item I)
    comprising steps of:
    • (Step B)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00062
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00063
  • (wherein each symbol is as defined in Item I)
    to obtain a compound shown by formula (X3), or a salt thereof:
  • Figure US20140011995A1-20140109-C00064
  • (wherein each symbol is as defined in Item I);
    • (Step C)
  • reacting a compound shown by formula (X3) with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 72]

  • H2N—R6d  (V3)
  • (wherein R6d is as defined in Item II)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00065
  • (wherein each symbol is as defined in Item I or II); and
    • (Step D)
  • reacting a compound shown by formula (X4), or a salt thereof with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00066
  • (wherein each symbol is as defined in Item I).
    • (Item IV″)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00067
  • (wherein Rx is as defined in Item I)
    comprising steps of:
    • (Step B)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00068
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00069
  • (wherein each symbol is as defined in Item I)
    to obtain a compound shown by formula (X3), or a salt thereof:
  • Figure US20140011995A1-20140109-C00070
  • (wherein each symbol is as defined in Item I); and
    • (Step C)
  • reacting a compound shown by formula (X3) with a compound shown by formula (V3), or a salt thereof:

  • [Chemical formula 79]

  • H2N—R6d  (V3)
  • (wherein R6d is as defined in Item II)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00071
  • (wherein each symbol is as defined in Item I or II);
    • (Step D)
  • reacting a compound shown by formula (X4), or a salt thereof with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00072
  • (wherein each symbol is as defined in Item I); and
    • (Step E)
  • reacting with a compound shown by formula (V6), or a salt thereof:

  • [Chemical formula 82]

  • RX—NH2  (V6)
  • (wherein Rx is as defined in Item I).
    • (Item V)
  • A method according to Item IV, IV′, or IV″, wherein Step B and Step C are continuously performed.
    • (Item VI)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00073
  • (wherein Rx is as defined in Item I)
    comprising a step of reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00074
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00075
  • (wherein each symbol is as defined in Item I)
    and a compound shown by formula (V2′)

  • [Chemical formula 86]

  • NH4+Xd−  (V2′)
  • (wherein Xd− is a counter anion of ammonium cation) to obtain a compound shown by formula (X4′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00076
  • (wherein each symbol is as defined in Item I).
    • (Item VII)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00077
  • (wherein R′ is as defined in Item I)
    comprising steps of:
    • (Step B′)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00078
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00079
  • (wherein each symbol is as defined in Item I)
    and a compound shown by formula (V2′):

  • [Chemical formula 91]

  • NH4+Xd−  (V2′)
  • (wherein Xd− is a counter anion of ammonium cation)
    to obtain a compound shown by formula (X4′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00080
  • (wherein each symbol is as defined in Item I); and
    • (Step C′)
  • reacting a compound shown by formula (X4′) with a compound shown by formula (V3′):

  • [Chemical formula 93]

  • R6d-Ld  (V3′)
  • (wherein R6d is as defined in Item II, and Ld is a leaving group)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00081
  • (wherein each symbol is as defined in Item I or II).
    • (Item VII′)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00082
  • (wherein Rx is as defined in Item I) comprising steps of:
    • (Step B′)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00083
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00084
  • (wherein each symbol is as defined in Item I)
    and a compound shown by formula (V2′):

  • [Chemical formula 98]

  • NH4+Xd−  (V2′)
  • (wherein Xd− is a counter anion of ammonium cation)
    to obtain a compound shown by formula (X4′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00085
  • (wherein each symbol is as defined in Item I);
    • (Item C′)
  • reacting a compound shown by formula (X4′) with a compound shown by formula (V3′):

  • [Chemical formula 100]

  • R6d-Ld  (V3′)
  • (wherein R6d is as defined in Item II, and Ld is a leaving group)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00086
  • (wherein each symbol is as defined in Item I or II); and
    • (Step D)
  • reacting a compound shown by formula (X4) with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00087
  • (wherein each symbol is as defined in Item I).
    • (Item VII″)
  • A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
  • Figure US20140011995A1-20140109-C00088
  • (wherein Rx is as defined in Item I)
    comprising steps of:
    • (Step B′)
  • reacting a compound shown by formula (X2):
  • Figure US20140011995A1-20140109-C00089
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V2):
  • Figure US20140011995A1-20140109-C00090
  • (wherein each symbol is as defined in Item I)
    and a compound shown by formula (V2′):

  • [Chemical formula 106]

  • NH4+Xd−  (V2′)
  • (wherein Xd− is a counter anion of ammonium cation)
    to obtain a compound shown by formula (X4′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00091
  • (wherein each symbol is as defined in Item I);
    • (Step C′)
  • reacting a compound shown by formula (X4′) or a salt thereof with a compound shown by formula (V3′):

  • [Chemical formula 108]

  • R6d-Ld)
  • (wherein R6d is as defined in Item II and Ld is a leaving group)
    to obtain a compound shown by formula (X4), or a salt thereof:
  • Figure US20140011995A1-20140109-C00092
  • (wherein each symbol is as defined in Item I or II);
    • (Step D)
  • reacting a compound shown by formula (X4) with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
  • Figure US20140011995A1-20140109-C00093
  • (wherein each symbol is as defined in Item I); and
    • (Step E)
  • reacting with a compound shown by formula (V6), or a salt thereof:

  • [Chemical formula 111]

  • RX—NH2  (V6)
  • (wherein Rx is as defined in Item I).
    • (ItemVIII)
  • A method according to any one of Items I, IV, IV′, IV″, VI, VII, VII′, or VII″, wherein A compound shown by formula (X2) is obtained by reacting a compound shown by formula (X1):
  • Figure US20140011995A1-20140109-C00094
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (V1):
  • Figure US20140011995A1-20140109-C00095
  • (wherein Pd is lower alkyl optionally substituted by substituent E, and R3d and substituent E are as defined in Item I).
    • (Item IX)
  • A method according to any one of Items I, IV, IV′, IV″, VI, VII, VII′, or VII″, wherein a compound shown by formula (X2) is obtained by reacting a compound by formula (Z1):
  • Figure US20140011995A1-20140109-C00096
  • (wherein each symbol is as defined in Item I)
    with a compound shown by formula (Z2):
  • Figure US20140011995A1-20140109-C00097
  • (wherein each symbol is as defined in Item I).
    • (Item X)
  • A method according to any one of Items I to VII, IV′, IV″, VII′, and VII″, wherein Rx is carbocyclyl lower alkyl optionally substituted by substituent E.
    • (Item XI)
  • A method according to any one of Item I to VII, IV′, IV″, VII′, and VII″, wherein Rx is 2,4-difluorobenzyl.
    • Effect of the Invention
  • The present invention enables production of compound (Y1) and compound (Y2) useful as anti-HIV drugs having HIV integrase inhibitory activity in a short step as compared to conventional methods, so the compounds can be efficiently produced in a high yield. In addition, the present invention has a number of advantages, that use of a reaction reagent with toxicity can be avoided, use of harmful reaction can be avoided, use of an expensive reaction reagent can be avoided, use of an environmentally harmful reagent and solvent can be avoided, and the like. Therefore, the present invention is useful for the industrial production of anti-HIV drugs.
  • In addition, the crystals of compound (U1), compound (U2), and compound (U3) according to the present invention have advantages such as high stability to heat, high stability to light, high purification effect to remove impurities, easy handling, and/or small hygroscopy, and therefore, can be efficiently produced by utilizing those advantages.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a powder X-ray diffraction pattern of compound 12B obtained in Step 1 of Example 12. The ordinate represents peak intensity, and the abscissa represents a diffraction angle (2θ).
  • FIG. 2 is a powder X-ray diffraction pattern of compound 15A obtained in Example 15A. The ordinate represents peak intensity, and the abscissa represents a diffraction angle (2θ).
  • FIG. 3 is a powder X-ray diffraction pattern of compound 15B obtained in Example 15B. The ordinate represents peak intensity, and the abscissa represents a diffraction angle (2θ).
    •  BEST MODE FOR CARRYING OUT THE INVENTION
  • Hereinafter, the terms described in the present specification will be described. Each term alone or in combination with other terms has the same meaning.
  • The term “halogen” encompasses fluorine, chlorine, bromine, and iodine atoms.
  • The term “lower alkyl” encompasses linear or branched alkyl having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, further preferably 1 to 4 carbon atoms, most preferably 1 or 2 carbon atoms. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl. Examples of preferred embodiments of “lower alkyl” include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and n-pentyl. Examples of more preferred embodiments thereof include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • The term “lower alkenyl” encompasses linear or branched alkenyl having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, further preferably 2 to 4 carbon atoms and having one or more double bonds at an arbitrary position. Specifically, the “lower alkenyl” encompasses vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, and the like. Examples of preferred embodiments of “lower alkenyl” include vinyl, allyl, propenyl, isopropenyl, and butenyl. Examples of particularly preferred embodiments thereof include allyl.
  • The lower allyl moieties of “lower alkyloxy”, “lower alkylcarbonyl”, “lower alkyloxycarbonyl”, “carbocyclyl lower alkyl”, “heterocyclyl lower alkyl”, “halogeno lower alkyl”, “carbocyclyl lower alkyloxy”, “heterocyclyl lower alkyloxy”, “halogeno lower alkyloxy”, “lower alkyloxy lower alkyl”, “lower alkyloxy lower alkyloxy”, “lower alkylamino”, “lower alkylcarbonylamino”, “lower alkylaminocarbonyl”, “lower alkylsulfonyl”, “lower alkylsulfonylamino”, “carbocyclyl lower alkylthio”, “heterocyclyl lower alkylthio”, “carbocyclyl lower alkylamino”, and “heterocyclyl lower alkylamino” are also the same as the “lower alkyl” described above.
  • The halogen moieties of “halogeno lower alkyl” and “halogeno lower alkyloxy” are also the same as the “halogen” described above. In this context, the “lower alkyl” and the “lower alkyloxy” may be substituted by one halogen atom or more identical or different halogen atoms at their respective arbitrary positions on the alkyl groups.
  • The term “carbocyclyl” means carbocyclyl having 3 to 20 carbon atoms, preferably 3 to 16 carbon atoms, more preferably 4 to 12 carbon atoms and encompasses cycloalkyl, cycloalkenyl, aryl, non-aromatic condensed carbocyclyl, and the like.
  • The “cycloalkyl” means carbocyclyl having 3 to 16 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 4 to 8 carbon atoms and encompasses, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
  • The “cycloalkenyl” encompasses a group having one or more double bonds at an arbitrary position in the ring of the cycloalkyl. Examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptynyl, cyclooctynyl, and cyclohexadienyl.
  • The “aryl” encompasses phenyl, naphthyl, anthryl, phenanthryl, and the like. Particularly, phenyl is preferred.
  • The “non-aromatic condensed carbocyclyl” encompasses a group in which two or more cyclic groups selected from the “cycloalkyl”, “cycloalkenyl”, and “aryl” described above are condensed. Examples thereof include indanyl, indenyl, tetrahydronaphthyl, fluorenyl, and adamantyl.
  • Examples of preferred embodiments of “carbocyclyl” include cycloalkyl, aryl, and non-aromatic condensed carbocyclyl. Specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and phenyl.
  • The carbocyclyl moieties of “carbocyclyl lower alkyl”, “carbocyclyl lower alkyloxy”, “carbocyclyl lower alkylthio”, “carbocyclyl lower alkylamino”, “carbocyclyloxy”, “carbocyclylcarbonyl”, and “carbocyclylaminocarbonyl” are also the same as the ‘carbocyclyl’ described above. In this context, the “carbocyclyl lower alkyl” in particularly preferred embodiments is benzyl.
  • Examples of preferred embodiments of “carbocyclyl lower alkyloxy” include benzyloxy.
  • Examples of preferred embodiments of “carbocyclyl lower alkylthio” include benzylthio.
  • Examples of preferred embodiments of “carbocyclyl lower alkylamino” include benzylamino.
  • Examples of preferred embodiments of “carbocyclyloxy” include phenyloxy.
  • Examples of preferred embodiments of “carbocyclylcarbonyl” include phenylcarbonyl.
  • Examples of preferred embodiments of “carbocyclylaminocarbonyl” include phenylaminocarbonyl.
  • The term “heterocyclyl” encompasses heterocyclyl having, in the ring, one or more identical or different heteroatoms arbitrarily selected from O, S, and N, such as heteroaryl, none-aromatic heterocyclyl, bicyclic condensed heterocyclyl, and tricyclic condensed heterocyclyl.
  • Examples of the “heteroaryl” include 5- to 6-membered aromatic cyclyl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, and thiadiazolyl.
  • Examples of the “none-aromatic heterocyclyl” include dioxanyl, thiiranyl, oxiranyl, oxetanyl, oxathiolanyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydrofuryl, tetrahydropyranyl, dihydrothiazolyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, dihydrooxazinyl, hexahydroazepinyl, tetrahydrodiazepinyl, tetrahydropyridazinyl, hexahydropyrimidinyl, and dioxolanyl.
  • Examples of the “bicyclic condensed heterocyclyl” include indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, thienopyridyl, thienopyrrolyl, thienopyrazolyl, thienopyrazinyl, furopyrrolyl, thienothienyl, imidazopyridyl, pyrazolopyridyl, thiazolopyridyl, pyrazolopyrimidinyl, pyrazolotriazinyl, pyridazolopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl, naphthyridinyl, dihydrothiazolopyrimidinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzofuryl, dihydrobenzoxazinyl, dihydrobenzimidazolyl, tetrahydrobenzothienyl, tetrahydrobenzofuryl, benzodioxolyl, benzodioxonyl, chromanyl, chromenyl, octahydrochromenyl, dihydrobenzodioxynyl, dihydrobenzooxedinyl, dihydrobenzodioxepinyl, and dihydrothienodioxynyl.
  • Examples of the “tricyclic condensed heterocyclyl” include carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl, imidazoquinolyl, and tetrahydrocarbazolyl.
  • Examples of preferred embodiments of “heterocyclyl” include 5- to 6-membered heteroaryl or none-aromatic heterocyclyl, and tricyclic condensed heterocyclyl.
  • The heterocyclyl moieties of “heterocyclyl lower alkyl”, “heterocyclyl lower alkyloxy”, “heterocyclyl lower alkylthio”, “heterocyclyl lower alkylamino”, “heterocyclyloxy”, “heterocyclylcarbonyl”, and “heterocyclylaminocarbonyl” are also the same as the “heterocyclyl” described above. In this context, the “heterocyclyl lower alkyl” in particularly preferred embodiments is pyridylmethyl.
  • Examples of preferred embodiments of “heterocyclyl lower alkyloxy” include pyridylmethyloxy.
  • Examples of preferred embodiments of “heterocyclyl lower alkylthio” include pyridylmethylthio.
  • Examples of preferred embodiments of “heterocyclyl lower alkylamino” include pyridylmethylamino.
  • Examples of preferred embodiments of “heterocyclyloxy” include pyridyloxy.
  • Examples of preferred embodiments of “heterocyclylcarbonyl” include pyridylcarbonyl.
  • Examples of preferred embodiments of “heterocyclylaminocarbonyl” include pyridylaminocarbonyl.
  • The phrase “Step B and Step C are continuously performed” means that after the completion of Step B, Step C is carried out without performing the isolation operation (e.g., crystallization and collection by filtration, and distillation), extraction operation, and column chromatography purification of the product of Step B. Step B and Step C may be performed in the same or different reactors.
  • The term “lower alkyl optionally substituted by substituent E” means that “lower alkyl” is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent E. When the lower alkyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other. Examples thereof include methyl, fluoromethyl, trifluoromethyl, chlorodifluoromethyl, and
  • Figure US20140011995A1-20140109-C00098
  • The term “carbocyclyl optionally substituted by substituent E” means that “carbocyclyl” is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent E. When the carbocyclyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other. The “carbocyclyl optionally substituted by substituent E” encompasses, for example, fluorophenyl, difluorophenyl, and methoxyfluorophenyl.
  • The term “carbocyclyl lower alkyl optionally substituted by substituent E” means that “carbocyclyl” and/or “lower alkyl” is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent E. When the carbocyclyl and/or the lower alkyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other. The “carbocyclyl lower alkyl optionally substituted by substituent E” encompasses, for example, 4-fluorobenzyl, 2,4-difluorobenzyl, 4-methoxy-2-fluorobenzyl, and 4-methoxyphenyldifluoromethyl.
  • The terms “lower alkyloxy optionally substituted by substituent E”, “carbocyclyl lower alkyloxy optionally substituted by substituent E”, “heterocyclyl lower alkyloxy optionally substituted by substituent E”, and “lower alkenyl optionally substituted by substituent E” are also defined similarly.
  • The term “carbocyclyl optionally substituted by substituent F” means that ‘carbocyclyl’ is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent F. When the carbocyclyl is bonded to a plurality of substituents, these substituents may be the same as or different from each other. The “carbocyclyl optionally substituted by substituent F” encompasses, for example, fluorophenyl, difluorophenyl, and methoxyfluorophenyl.
  • The term “carbocyclyl lower alkyloxy optionally substituted by substituent F” means that the ‘carbocyclyl’ moiety is unsubstituted or is bonded to one or more chemically acceptable substituents selected from substituent F. When the carbocyclyl moiety is bonded to a plurality of substituents, these substituents may be the same as or different from each other. The “carbocyclyl lower alkyloxy optionally substituted by substituent F” encompasses, for example, fluorobenzyloxy, difluorobenzyloxy, and methoxyfluorobenzyloxy.
  • The terms “heterocyclyl optionally substituted by substituent F”, “heterocyclyl lower alkyloxy optionally substituted by substituent F”, “carbocyclyl lower alkylthio optionally substituted by substituent F”, “heterocyclyl lower alkylthio optionally substituted by substituent F”, “carbocyclyl lower alkylamino optionally substituted by substituent F”, “heterocyclyl lower alkylamino optionally substituted by substituent F”, “carbocyclyloxy optionally substituted by substituent F”, “heterocyclyloxy optionally substituted by substituent F”, “carbocyclylcarbonyl optionally substituted by substituent F”, “heterocyclylcarbonyl optionally substituted by substituent F”, “carbocyclylaminocarbonyl optionally substituted by substituent F”, and “heterocyclylaminocarbonyl optionally substituted by substituent F” are also defined similarly.
  • The phrase “two R3es in —N(R3e)2 together with the adjacent nitrogen atom may form a heterocycle” encompasses, for example, formulas shown below:
  • Figure US20140011995A1-20140109-C00099
  • The “amino protective group” can be any general protective group for the amino group and exemplified by amino protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). The “amino protective group” is preferably a tert-butyloxycarbonyl or benzyloxycarbonyl group.
  • The “carboxyl protective group” can be any general protective group for the carboxyl group and exemplified by carboxyl protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). Preferred examples thereof include methyl, ethyl, tert-butyl, methoxymethyl, allyl, benzyl, and p-methoxybenzyl groups.
  • Examples of the “counter anion of ammonium cation” represented by Xd include halogen−, CH3COO−, HCOO−, NO3 −, BF4 −, PF6 −, HO−, Ph-SO3 −, CH3-Ph-SO3 −, CH3—SO3 −, PO4 3−, SO4 2− and HSO4 −. The “counter anion of ammonium cation” is preferably halogen−, CH3COO−, NO3 −, or SO4 2−. In the case of divalent or trivalent anion, the counter anion represents that each NH4 +cation is in an uncharged state by the binding of two or three molecules thereof. Specific examples of NH4 +Xd− include NH4 +Cl−, NH4 +CH3COO−, (NH4 +)2SO4 2−, and (NH4 +)3PO4 3−.
  • The “leaving group” refers to a substituent that is eliminated through nucleophilic reaction. Examples thereof include halogen, —O—SO2—CH3, —O—SO2—CF3, —O—SO2-Ph, and —O—SO2-Ph-CH3. The “leaving group” is preferably halogen.
  • (In this context, Ph represents a phenyl group.)
  • Examples of the salt include basic salts or acidic salts.
  • Examples of the basic salts include: alkali metal salts such as sodium salt, potassium salt, and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; aliphatic amine salts such as trimethylamine salt, triethylamine salt, dicyclohexylamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, procaine salt, meglumine salt, diethanolamine salt, and ethylenediamine salt; aralkylamine salts such as N,N-dibenzylethylenediamine and benethamine salt;
  • heterocyclic aromatic amine salts such as pyridine salt, picoline salt, quinoline salt, and isoquinoline salt;
    quaternary ammonium salts such as tetramethylammonium salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammonium salt, methyltrioctylammonium salt, and tetrabutylammonium salt; and basic amino acid salts such as arginine salt and lysine salt.
  • Examples of the acidic salts include: inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, and perchlorate; organic acid salts such as acetate, propionate, lactate, maleate, fumarate, tartrate, malate, citrate, and ascorbate; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, and p-toluenesulfonate; and acidic amino acids such as aspartate and glutamate.
  • The salt derived from the carboxyl or hydroxyl group is preferably a basic salt, more preferably an alkali metal salt. Particularly preferred examples of the salt include sodium salt, lithium salt, and potassium salt. The most preferred example of the salt includes sodium salt.
  • The salt derived from the amine site is preferably an acidic salt, more preferably an inorganic acid salt. Examples of preferable salts include hydrochloride and sulfate.
  • Hereinafter, the production method of the present invention will be described.
    • (Step A)
  • This step is the step of reacting compound (X1) with compound (V1) to obtain a solution containing compound (X2), as shown below in the reaction formula.
  • In this context, the “solution” means compound (X2) in a dissolved state and also encompasses compound (X2) in a suspension or slurry form in which the compound is dispersed without being completely dissolved. This holds true for the description below, and the “solution” according to the present specification encompasses suspension and slurry forms.
  • Figure US20140011995A1-20140109-C00100
  • (wherein each symbol is as defined above).
  • The compound (X1) may be a commercially available reagent or can be obtained by a method known in the art.
  • When R1d is halogen, nucleophilic substitution reaction may be performed, if desired in the presence of a base, in a solvent supplemented with an alcohol reagent such as a lower alcohol optionally substituted by substituent E, a carbocyclyl lower alkyl alcohol optionally substituted by substituent E, a heterocyclyl lower alkyl alcohol optionally substituted by substituent E, or (R1e)3Si—OH to obtain compound (X1) wherein R1d is lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e)3.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R1d include methoxy, ethoxy, isopropoxy, trichloromethoxy, and trifluoromethoxy. Methoxy is preferred.
  • Examples of the “carbocyclyl lower alkyloxy optionally substituted by substituent E” represented by R1d include benzyloxy, phenethyloxy, 2,4-difluorobenzyloxy, and 4-methoxybenzyloxy. Benzyloxy is preferred.
  • Examples of the “heterocyclyl lower alkyloxy optionally substituted by substituent E” represented by R1d include pyridylmethyloxy.
  • R1d in preferred embodiments is hydrogen, chloro, bromo, methoxy, or benzyloxy.
  • When R1d is —OSi(R1e)3, R1e in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, or the like.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R2d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R2d include benzyl and 4-methoxybenzyl.
  • Examples of the “heterocyclyl lower alkyl optionally substituted by substituent E” represented by R3d include pyridylmethyl.
  • R2d in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, 4-methoxybenzyl, or the like.
  • The reaction solvent used in the nucleophilic substitution reaction for obtaining the compound (X1) is preferably an aprotic solvent. Examples thereof include acetonitrile, tetrahydrofuran, dioxane, diethyl ether, dichloromethane, chloroform, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, and mixed solvents thereof.
  • The base can be any base capable of deprotonating the alcohol reagent. Examples thereof include n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, sodium ethoxide, sodium hydride, lithium diisopropylamide, and lithium bis(trimethylsilyl)amide.
  • The amount of the base is approximately 1.0 to 3.0 molar equivalents with respect to compound (X1) wherein R1d is halogen.
  • The amount of the alcohol reagent is approximately 0.5 to 1.5 molar equivalents with respect to compound (X1) wherein R1d is halogen.
  • The reaction temperature is usually 0° C. to reflux temperature, preferably room temperature to 50° C.
  • The reaction time is usually 10 minutes to 50 hours, preferably 1 to 4 hours.
  • The compound (V1) can be obtained as a commercially available reagent or by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by Pd include methyl, ethyl, and trifluoromethyl. Pd in preferred embodiments is methyl.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R3d include methoxy and ethoxy.
  • When R3d is —N(R3e)2, examples of the “lower alkyl optionally substituted by substituent E” represented by R3′ include methyl, ethyl, and trifluoromethyl.
  • R3d in preferred embodiments is —N(CH3)2, —OCH3, or pyrrolidinyl.
  • Examples of the solvent of the reaction include acetonitrile, tetrahydrofuran, dioxane, diethyl ether, dichloromethane, chloroform, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, and mixed solvents thereof.
  • The amount of the compound (V1) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (X1), or the compound (V1) may be used as a solvent.
  • The reaction temperature is usually 0° C. to reflux temperature, preferably room temperature.
  • The reaction time is usually 30 minutes to 50 hours, preferably 2 to 8 hours.
  • The compound (X2) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
    • (Step A′)
  • Compound (X2) may be obtained through the following reaction:
  • Figure US20140011995A1-20140109-C00101
  • (wherein R5d is halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO2—R5e′; and each of the other symbols is as defined above).
  • The compound (Z1) may be a commercially available reagent or can be obtained by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R2d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R2d include benzyl and 4-methoxybenzyl.
  • Examples of the “heterocyclyl lower alkyl optionally substituted by substituent E” represented by R2d include pyridylmethyl.
  • R2d in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, 4-methoxybenzyl, or the like.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by led include methoxy and ethoxy.
  • When R3d is —N(R3e)2, examples of the “lower alkyl optionally substituted by substituent E” represented by R3e include methyl, ethyl, and trifluoromethyl.
  • R3d in preferred embodiments is —N(CH3)2, —OCH3, or pyrrolidinyl.
  • The compound (Z2) may be a commercially available reagent or can be obtained by a method known in the art.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R1d include methoxy, ethoxy, isopropoxy, trichloromethoxy, and trifluoromethoxy. Methoxy is preferred.
  • Examples of the “carbocyclyl lower alkyloxy optionally substituted by substituent E” represented by R1d include benzyloxy, phenethyloxy, 2,4-trifluorobenzyloxy, and 4-methoxybenzyloxy. Benzyloxy is preferred.
  • Examples of the “heterocyclyl lower alkyloxy optionally substituted by substituent E” represented by R1d include pyridylmethyloxy.
  • R1d in preferred embodiments is hydrogen, chloro, bromo, methoxy, or benzyloxy.
  • Examples of preferred embodiments of R5d include chloro, bromo, methoxy, ethoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy.
  • Examples of the solvent of the reaction include acetonitrile, tetrahydrofuran, dioxane, diethyl ether, dichloromethane, chloroform, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, and mixed solvents thereof.
  • The amount of the compound (Z2) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (Z1).
  • The reaction temperature is usually −10° C. to reflux temperature, preferably room temperature.
  • The reaction time is usually 10 minutes to 10 hours, preferably 1 to 4 hours.
  • Tertiary amine is added, if necessary. Examples of the tertiary amine include pyridine, triethylamine, dimethylaminopyridine, and N-methylmorpholine.
  • The compound (X2) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated.
    • (Step B)
  • This step is the step of reacting compound (X2) with compound (V2), if desired in the presence of a base, to obtain a solution containing compound (X3) or a salt thereof, as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00102
  • (wherein each symbol is as defined above).
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R1d include methoxy, ethoxy, isopropoxy, trichloromethoxy, and trifluoromethoxy. Methoxy is preferred.
  • Examples of the “carbocyclyl lower alkyloxy optionally substituted by substituent E” represented by R1d include benzyloxy, phenethyloxy, 2,4-trifluorobenzyloxy, and 4-methoxybenzyloxy. Benzyloxy is preferred.
  • Examples of the “heterocyclyl lower alkyloxy optionally substituted by substituent E” represented by R1d include pyridylmethyloxy.
  • R1d in Preferred embodiments is hydrogen, chloro, bromo, methoxy, or benzyloxy.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R2d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R2d include benzyl and 4-methoxybenzyl.
  • Examples of the “heterocyclyl lower alkyl optionally substituted by substituent E” represented by R2d include pyridylmethyl.
  • R2d in preferred embodiments is methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, 4-methoxybenzyl, or the like.
  • Examples of the “lower alkyloxy optionally substituted by substituent E” represented by R3d include methoxy and ethoxy.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R3e include methyl, ethyl, and trifluoromethyl.
  • R3d in preferred embodiments is —N(CH3)2, —OCH3, or pyrrolidinyl.
  • The compound (V2) can be obtained as a commercially available reagent or by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R4d include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by R4d include benzyl and 4-methoxybenzyl.
  • Examples of the “heterocyclyl lower alkyl optionally substituted by substituent E” represented by R4d include pyridylmethyl.
  • Examples of preferred embodiments of R4d include methyl, ethyl, n-propyl, isopropyl, tert-butyl, benzyl, and 4-methoxybenzyl. Particularly, methyl or ethyl is preferred.
  • Examples of preferred embodiments of R5d include chloro, bromo, methoxy, ethoxy, acetoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and p-toluenesulfonyloxy. Particularly, chloro, methoxy, or ethoxy is preferred.
  • Examples of the reaction solvent include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the base include n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, sodium ethoxide, sodium hydride, lithium diisopropylamide, and lithium bis(trimethylsilyl)amide.
  • The amount of the base used is approximately 1.0 to 5.0 molar equivalents with respect to compound (X2).
  • The amount of the compound (V2) used is approximately 1.5 to 5.0 molar equivalents with respect to compound (X2), or the compound (V2) may be used as a solvent.
  • The reaction temperature is usually −80° C. to reflux temperature, preferably −20° C. to 50° C. The reaction time is usually 30 minutes to 50 hours, preferably 2 to 12 hours.
  • The compound (X3) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated. Preferably, the compound (X3) is isolated as crystals free from impurities by crystallization.
    • (Step B′)
  • This step is the step of reacting compound (X2) with compound (V2) and compound (V2′), if desired in the presence of a base, to obtain compound (X4′) or a salt thereof as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00103
  • (wherein each symbol is as defined above).
  • Examples and preferred embodiments of R1d, R2d, R3d, R4d and R5d in the formulae (X2) and (V2) are the same as above.
  • Examples of the reaction solvent include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the base include n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, sodium ethoxide, sodium hydride, lithium diisopropylamide, and lithium bis(trimethylsilyl)amide.
  • The amount of the base used is approximately 1.0 to 5.0 molar equivalents with respect to compound (X2).
  • The amount of the compound (V2) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (X2), or the compound (V2) may be used as a solvent.
  • The reaction temperature is usually −80° C. to reflux temperature, preferably −20° C. to 30° C.
  • The reaction time is usually 10 minutes to 10 hours, preferably 30 minutes to 4 hours.
  • Subsequently, compound (V2′) is added to the reaction solution and reacted therewith.
  • Examples of the compound (V2′) include ammonium acetate, ammonium chloride, ammonium bromide, ammonium sulfate, ammonium bisulfate, ammonium formate, ammonium nitrate, ammonium hydroxide, ammonium phosphate, NH4 +BF4 −, NH4PF6 −, NH4 +Ph-SO 3 −, NH4 +CH3-Ph-SO3 −, and NH4 +CH3—SO3 −. The compound (V2′) is preferably ammonium acetate, ammonium chloride, ammonium sulfate, ammonium bisulfate, or ammonium formate. (In this context, Ph represents a phenyl group.)
  • The amount of the compound (V2′) used is approximately 1.0 to 3.0 molar equivalents with respect to compound (X2).
  • The reaction temperature is usually 0° C. to reflux temperature, preferably 20° C. to 80° C.
  • The reaction time is usually 10 minutes to 10 hours, preferably 30 minutes to 4 hours.
  • The compound (X4′) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated. Preferably, the compound (X4′) is isolated as crystals free from impurities by crystallization.
    • (Step C)
  • This step is the step of reacting compound (X3) or a salt thereof with compound (V3) or a salt thereof to obtain cot/mound (X41 or a salt thereof as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00104
  • (wherein each symbol is as defined above).
  • Examples and preferred embodiments of R1d, R2d, and R4d in the formula (X3) are the same as those described above in Step B.
  • The compound (V3) can be obtained as a commercially available reagent or by a method known in the art.
  • Examples of the “lower alkyl optionally substituted by substituent E” represented by R6d include HC(═O)—CH2—, CH(—OH)2—CH2—, CH3O—CH(—OH)—CH2—, dimethoxyethyl, diethoxyethyl, HO—CH2—CH(—OH)—CH2—,
  • Figure US20140011995A1-20140109-C00105
  • Examples of the “lower alkenyl optionally substituted by substituent E” represented by R6d include CH2═CH—CH2—.
  • Examples of the reaction solvent include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, methanol, ethanol, isopropanol, and mixed solvents thereof.
  • The amount of the compound (V3) used is approximately 1.0 to 2.0 molar equivalents with respect to compound (X3).
  • The reaction temperature is usually 0° C. to reflux temperature, preferably 20° C. to 70° C.
  • The reaction time is usually 30 minutes to 50 hours, preferably 2 to 12 hours.
  • When R6d in the formed compound (X4) is not an aldehyde group or a group having an equivalent thereof, such as HC(═O)—CH2—, CH3O—CH(—OH)—CH2—, or CH(—OH)2—CH2—, this moiety can be converted to HC(═O)—CH2—, CH3O—CH(—OH)—CH2—, or CH(—OH)2—CH2—, which is an aldehyde group or a group having an equivalent thereof, by deprotection methods for protective groups in aldehyde groups described in Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons) or a method known in the art as described in International Publication No. WO 2006/116764 or 2006/088173.
  • When R6d in compound (X4) is, for example, dimethoxyethyl, this moiety can be converted to HC(═O)—CH2— by the addition of an acid to the solution containing compound (X4). The acid is not particularly limited and is exemplified by hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, maleic acid, and oxalic acid. The amount of the acid used is 2.0 to 10.0 molar equivalents with respect to compound (X4). Acetic acid or formic acid may be used as a solvent and may be used as a mixture with any of the acids described above.
  • The reaction temperature is usually approximately 0° C. to 80° C., preferably 10° C. to 40° C.
  • The reaction time is usually 30 minutes to 50 hours, preferably 2 to 12 hours.
  • When the amino group is protected with an amino protective group, a compound with a deprotected amino group can also be obtained by deprotection methods for protective groups in amino groups described in Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons) or a method known in the art. The order of deprotection reactions can be changed appropriately.
  • When R6d is an amino protective group, the amino protective group in compound (X4) can be subjected to deprotection reaction, followed by reaction with compound (V3′) in the subsequent step, as in Step C′ shown below, to obtain the compound (X4) of interest.
  • The compound (X4) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated. Preferably, the compound (X4) is isolated as crystals free from impurities by crystallization.
    • (Step C′)
  • This step is the step of reacting compound (X4′) or a salt thereof with compound (V3′), if desired in the presence of a base, to obtain compound (X4) or a salt thereof, as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00106
  • (wherein each symbol is as defined above).
  • Examples and preferred embodiments of R1d, R2d, R4d, and R6d in the formulae (X4′) and (V3′) are the same as those described above in Step B′ and Step C.
  • Examples of the “leaving group” represented by Ld include halogen, —O—SO2—CH3, —O—SO2—CF3, —O—SO2-Ph, and —O—SO2-Ph-CH3. Halogen is preferred. (In this context, Ph represents a phenyl group.)
  • When R6d in the formed compound (X4) does not have an aldehyde group or an equivalent thereof, such as HC(═O)—CH2—, CH3O—CH(—OH)—CH2—, or CH(—OH)2—CH2—, the method of converting this moiety to the aldehyde group or the equivalent thereof is also the same as above.
  • Examples of the reaction solvent include acetonitrile, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the base include potassium carbonate, cesium carbonate, sodium hydride, n-butyllithium, tert-butyllithium, sodium tert-butoxide, potassium-tert-butoxide, sodium tert-pentoxide, sodium methoxide, triethylamine, 4-dimethylaminopyridine, diisopropylethylamine, and DBU (1,8-diazabicyclo[5.4.0]undec-7-ene).
  • The amount of the base used is approximately 1.0 to 5.0 molar equivalents with respect to compound (X4′).
  • The amount of the compound (V3′) used is approximately 1.0 to 4.0 molar equivalents with respect to compound (X4′), or the compound (V3′) may be used as a solvent.
  • The reaction temperature is usually 0° C. to reflux temperature, preferably 20° C. to 80° C.
  • The reaction time is usually 30 minutes to 24 hours, preferably 1 to 8 hours.
  • The compound (X4) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated. Preferably, the compound (X4) is isolated as crystals free from impurities by crystallization.
    • (Step D)
  • This step is the step of reacting compound (X4) or a salt thereof with compound (V5) or compound (V5′), if desired in the presence of an acid, to obtain compound (X5) or compound (X5′), or a salt thereof, as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00107
  • (wherein R1d, R2d and R4d are as defined above; R6d is an aldehyde group or an equivalent thereof, such as HC(═O)—CH2—, CH3O—CH(—OH)—CH2—, or CH(—OH)2—CH2—; and when R6d is not the aldehyde or the equivalent thereof, the method described above in Step C is performed).
  • Examples and preferred embodiments of R1d, R2d, and R4d in the formulae (X4), (X5), and (X5′) are the same as above.
  • The compound (V5) and the compound (V5′) are commercially available reagents.
  • Examples of the reaction solvent include acetonitrile, tetrahydrofuran, dioxane, toluene, xylene, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylimidazolidinone, N-methylmorpholine, N-methylpyrrolidinone, and mixed solvents thereof.
  • Examples of the acid include acetic acid, trifluoroacetic acid, formic acid, and methanesulfonic acid. The amount of the acid used is 0.5 to 3.0 molar equivalents with respect to compound (X4).
  • The amount of the compound (V5) or the compound (V5′) used is approximately 1.0 to 2.0 molar equivalents with respect to compound (X4), or the compound (V5) or the compound (V5′) may be used as a solvent.
  • In this reaction, 1.0 to 5.0 molar equivalents of an alcohol reagent may be added, if desired, to thereby improve the reaction rate. The alcohol reagent is preferably methanol, ethanol, or isopropanol, particularly preferably methanol.
  • The reaction temperature is usually 20° C. to reflux temperature, preferably 60° C. to 80° C.
  • The reaction time is usually 30 minutes to 24 hours, preferably 1 to 8 hours.
  • The compound (X5) or the compound (X5′) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated. Preferably, the compound (X5) or the compound (X5′) is isolated as crystals free from impurities by crystallization.
    • (Step E)
  • This step is the step of reacting compound (X5) or compound (X5′), or a salt thereof with compound (V6) or a salt thereof to obtain compound (X6) or compound (X6′), as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00108
  • (wherein R1d and R2d are as defined above; RX is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E).
  • Examples of the “carbocyclyl optionally substituted by substituent E” represented by RX include phenyl, 2,4-difluorophenyl, and cyclohexyl.
  • Examples of the “heterocyclyl optionally substituted by substituent E” represented by RX include pyridyl, morpholinyl, and isoxazolyl.
  • Examples of the “carbocyclyl lower alkyl optionally substituted by substituent E” represented by RX include benzyl, 4-methoxybenzyl, and 2,4-difluorobenzyl.
  • Examples of the “heterocyclyl lower alkyl optionally substituted by substituent E” represented by RX include pyridylmethyl and isoxazolylmethyl.
  • Preferred examples of substituent E for the “carbocyclyl optionally substituted by substituent E”, “heterocyclyl optionally substituted by substituent E”, “carbocyclyl lower alkyl optionally substituted by substituent E”, and “heterocyclyl lower alkyl optionally substituted by substituent E” represented by RX include halogen, cyano, hydroxy, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogeno lower alkyl, lower alkyloxy, halogeno lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxycarbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulfonylamino. More preferred examples thereof include halogen, cyano, hydroxy, carboxy, formyl, amino, lower alkyl, halogeno lower alkyl, and lower alkyloxy. Further preferred examples thereof include halogen, lower alkyl, and lower alkyloxy. Halogen is most preferred.
  • RX in preferred embodiments is “carbocyclyl lower alkyl optionally substituted by substituent E” or “heterocyclyl lower alkyl optionally substituted by substituent E”. RX in more preferred embodiments is “carbocyclyl lower alkyl optionally substituted by substituent E”. RX in further preferred embodiments is “carbocyclyl lower alkyl optionally substituted by halogen”. RX in the most preferred embodiment is 2,4-difluorobenzyl.
  • When R1d is hydrogen, this moiety can be converted appropriately to halogen using a halogenating agent such as N-bromosuccinimide, N-chlorosuccinimide, or sulfuryl chloride.
  • R1d can be selected appropriately according to the reactivity of the reaction substrate. The order of these reactions can be changed appropriately.
  • When R2d is hydrogen, compound (X6) or compound (X6′) can be induced through general dehydration-condensation reaction (e.g., a method using a condensation agent, an acid chloride formation method, or an acid anhydride formation method) of the carboxyl group and compound (V6). For example, amide compound (X6) or compound (X6′) can be obtained through reaction at 0° C. to 60° C., preferably 10° C. to 40° C., for 1 hour to 48 hours, preferably 1 hour to 24 hours, in the presence of a dehydration-condensation agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, or WSC.
  • When R2d is not hydrogen, this moiety is converted to a carboxyl group through general deprotection reaction of the carboxyl protective group. Compound (X6) or compound (X6′) can be induced through the same dehydration-condensation reaction as above of the formed carboxyl group and compound (V6). The carboxyl protective group is exemplified by carboxyl protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). Preferred examples thereof include methyl, ethyl, tert-butyl, methoxymethyl, allyl, benzyl, and p-methoxybenzyl groups.
  • When R2d is “lower alkyl optionally substituted by substituent E”, compound (X6) or compound (X6′) can also be induced through aminolysis reaction using compound (V6).
  • The compound (X6) or the compound (X6′) may be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.) or can also be used in the next reaction without being isolated. Preferably, the compound (X6) or the compound (X6′) is isolated as crystals free from impurities by crystallization.
  • Compound X6 or compound X6′ may also be obtained by the following Step E′ and Step D′:
  • Figure US20140011995A1-20140109-C00109
  • (wherein R1d, R2d, R4d, R6d, and RX are as defined above; R6d is an aldehyde group or an equivalent thereof such as HC(═O)—CH2—, CH3O—CH(—OH)—CH2—, or CH(—OH)2—CH2—; and when R6d is not the aldehyde or the equivalent thereof, the method described above in Step C is performed).
    • (Step E′)
  • This step is the step of reacting compound (X5) or compound (X4), or a salt thereof with compound (V6) or a salt thereof to obtain compound (X4″).
  • Examples and preferred embodiments of R1d, R2d, R4d, and RX are the same as above.
  • When R2d is hydrogen, compound (X4″) can be induced through general dehydration-condensation reaction (e.g., a method using a condensation agent, an acid chloride formation method, or an acid anhydride formation method) of the carboxyl group and compound (V6). For example, amide compound (X6) can be obtained through reaction at 0° C. to 60° C., preferably 10° C. to 40° C., for 1 hour to 48 hours, preferably 1 hour to 24 hours, in the presence of a dehydration-condensation agent such as dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, or WSC.
  • When R2d is not hydrogen, this moiety is converted to a carboxyl group through general deprotection reaction of the carboxyl protective group. Compound (X4″) can be induced through the same dehydration-condensation reaction as above of the formed carboxyl group and compound (V6). The carboxyl protective group is exemplified by carboxyl protective groups described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons). Preferred examples thereof include methyl, ethyl, tert-butyl, methoxymethyl, allyl, benzyl, and p-methoxybenzyl groups. A methyl group is particularly preferred.
  • When R2d is “lower alkyl optionally substituted by substituent E”, compound (X4″) can also be induced through aminolysis reaction of compound (V6).
    • (Step D′)
  • This step is the step of reacting the compound (X4′) obtained in Step E′ with compound (V5) or compound (V5′), if desired in the presence of an acid, to obtain compound (X6) or compound (X6′), or a salt thereof.
    • (Step F)
  • This step is the step of obtaining compound (Y1) or compound (Y2), or a salt thereof from compound (X6) or compound (X6′), as shown below in the reaction formula:
  • Figure US20140011995A1-20140109-C00110
  • (wherein each symbol is as defined above).
  • Examples and preferred embodiments of RS are as defined above.
  • When R1d is lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e)3, this moiety can be converted to a hydroxy group through hydroxy deprotection reaction known in the art described in, for example, Protective Groups in Organic Synthesis, Theodora W Greene (John Wiley & Sons).
  • Specifically, when R1d is methyloxy, this moiety can be converted to a hydroxy group using a reagent such as (CH3)3—Si—I, BBr3, or BF3.Et2O. When R1d is benzyloxy, this moiety can be converted to a hydroxy group using Pd—C/H2 gas, a Raney-Ni reagent, or the like. When R1d is —OSi(CH3)3, this moiety can be converted to a hydroxy group using a tetramethylammonium fluoride reagent.
  • When R1d is halogen, this moiety can be converted to a hydroxy group by reaction with potassium trimethylsilanolate or lithium trimethylsilanolate and the subsequent addition of an aqueous solution of an inorganic acid. Examples of other conditions for the conversion reaction of halogen to a hydroxy group also include use of sodium hydride/water (Bioorganic Medicinal Chemistry Letters, 17, 1713, 2007), potassium hydroxide/tris(dibenzylideneacetone)dipalladium (Pd2 dba3)/di-tert-butylarylphosphine (Journal of the American Chemical Society, 128, 10694, 2006), potassium phosphate hydrate (K3PO4.H2O)/tris(dibenzylideneacetone)dipalladium (Pd2 dba3)/tri-tert-butylphosphine (Tetrahedron Letters, 48, 473, 2007). As described above, the halogen represented by R1d in the starting material may be derivatized directly. Thus, this approach requires a smaller number of reaction steps and may construct a more advantageous industrial production method, compared with the method involving alcohol protection and/or deprotection reactions.
  • When R1d is hydrogen, this R1d may be converted to halogen through reaction with a halogenating agent such as N-bromosuccinimide, N-chlorosuccinimide, or sulfuryl chloride, followed by reaction with potassium trimethylsilanolate or lithium trimethylsilanolate and the subsequent addition of an aqueous solution of an inorganic acid in the same way as above to induce a hydroxy group. Accordingly, R1d can be selected appropriately from among these substituents according to the reactivity of the reaction substrate.
  • In the step, the order of these reactions can be changed appropriately.
  • The compound (Y1) or the compound (Y2) can be isolated by a general purification method (extraction, distillation, column chromatography, crystallization, etc.).
  • The compound (Y1) or the compound (Y2) can be converted to a salt by the desired method. The salt is preferably a basic salt, more preferably an alkali metal salt such as sodium salt, potassium salt, or lithium. The most preferred example thereof includes sodium salt.
  • The salt of compound (Y1) or compound (Y2) can be deposited by dissolving the compound (Y1) or the compound (Y2) in an organic solvent or a mixed solution of an organic solvent and water and adding an aqueous alkali solution or an organic base to the solution, followed by stirring. This dissolution is performed by heating, if necessary. Also, the salt deposition is performed by cooling, if necessary.
  • For example, ethanol, methanol, isopropyl alcohol, acetone, acetonitrile, tetrahydrofuran, or dichloromethane may be used as the organic solvent.
  • In the present invention, preferably, the steps described above can be combined arbitrarily to obtain compound (Y1) or compound (Y2), or a salt thereof. Also, one or two or more chemical reactions well known by those skilled in the art may be combined appropriately before and/or after each step.
  • Hereinafter, the present invention will be described more specifically with reference to Examples and Test Examples of the present invention. However, the present invention is not limited to them. Each symbol used in Examples is as follows:
    • Me: Methyl Et: Ethyl Bn: Benzyl Ph: Phenyl DMI: Dimethylimidazolidinone THF: Tetrahydrofuran
  • WSC: N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide
    HATU: O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
    DBU: 1,8-diazabicyclo[5.4.0]-7-undecene
    • DMF: N,N-dimethylformamide
  • HOBt: 1-hydroxybenzotriazole
    • NBS: N-bromosuccinimide Example 1
  • Figure US20140011995A1-20140109-C00111
    • Step 1
  • A THF (3 ml) solution of benzyl alcohol (1.00 g, 9.25 mmol) was added to a THF (4 ml) suspension of sodium tert-pentoxide (2.55 g, 23.2 mmol) at room temperature in a nitrogen atmosphere, and the mixture was stirred at 40° C. for 2 hours. This reaction solution was cooled in an ice bath, and a THF (3 ml) solution of compound 1A (1.53 g, 10.2 mmol) was added dropwise thereto at 0-10° C. The reaction solution was stirred at room temperature for 2 hours, and 2 N hydrochloric acid (15 ml) was then added thereto, followed by extraction two times with ethyl acetate. The combined extracts were washed with water, a saturated aqueous solution of sodium bicarbonate, water, and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained oil was purified by silica gel column chromatography (n-hexane-ethyl acetate: 4:1, v/v) to obtain 1.89 g (yield: 92%) of compound 1B as an oil.
  • 1H-NMR (CDCl3) δ: 3.56 (2H, s), 3.71 (3H, s), 4.14 (2H, s), 4.59 (2H, s), 7.27-7.42 (5H, m).
    • Step 2
  • Compound 1B (1.80 g, 8.1 mmol) was dissolved in 1,4-dioxane (18 mL). To the solution, N,N-dimethylformamide dimethyl acetal (1.45 g, 12.2 mmol) was added, and the mixture was stirred at room temperature for 6 hours. The reaction solution was concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 1:4, v/v) to obtain 1.77 g (yield: 79%) of compound 1C as an oil.
  • 1H-NMR (CDCl3) δ: 2.90 (3H, br), 3.25 (3H, br), 3.69 (3H, s), 4.45 (2H, s), 4.59 (2H, s), 7.24-7.40 (5H, m), 7.73 (s, 1H).
    • Step 3
  • Sodium tert-butoxide (2.55 g, 23.2 mmol), dimethyl oxalate (639 mg, 5.41 mmol), and DMI (3 ml) were added to a three-neck flask in a nitrogen atmosphere, and a DMI (2 ml) solution of compound 1C (0.50 g, 1.80 mmol) was added dropwise thereto at 25-30° C. After stirring at room temperature for 7 hours, 2 N hydrochloric acid (10 ml) was added thereto, and the mixture was stirred at room temperature for 15 hours. After extraction two times with ethyl acetate, the combined extracts were washed with water, a saturated aqueous solution of sodium bicarbonate, water, and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 2:1→1:1, v/v) to obtain 488 mg (yield: 85%) of compound 1D as white crystals.
  • 1H-NMR (CDCl3) δ: 3.89 (3H, s), 3.93 (3H, s), 5.34 (2H, s), 7.32-7.40 (3H, m), 7.45-7.49 (2H, m), 8.50 (1H, s).
    • Example 2
  • Figure US20140011995A1-20140109-C00112
    • Step 1
  • A DMI (3 ml) solution of benzyl alcohol (0.66 g, 6.1 mmol) was added to a DMI (4 ml) suspension of sodium tert-pentoxide (1.67 g, 15.2 mmol) at room temperature in a nitrogen atmosphere, and the mixture was stirred at 40° C. for 2 hours. This reaction solution was cooled in an ice bath, and a DMI (3 ml) solution of compound 2A (1.10 g, 6.68 mmol) was added dropwise thereto at 0-10° C. The reaction solution was stirred at 0-5° C. for 2 hours and at room temperature for 3 hours, and 2 N hydrochloric acid (15 ml) was then added thereto, followed by extraction two times with ethyl acetate. The combined extracts were washed with water, a saturated aqueous solution of sodium bicarbonate, water, and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained oil was purified by silica gel column chromatography (n-hexane-ethyl acetate: 4:1, v/v) to obtain 1.29 g (yield: 90%) of compound 2B as an oil.
  • 1H-NMR (CDCl3) δ: 1.25 (3H, t, J=7.2 Hz), 3.54 (2H, s), 4.14 (2H, s), 4.17 (2H, q, J=7.2 Hz), 4.59 (2H, s), 7.28-7.40 (5H, m).
    • Step 2
  • Compound 2B (9.73 g, 41.2 mmol) was dissolved in toluene (45 mL). To the solution, N,N-dimethylformamide dimethyl acetal (7.36 g, 61.8 mmol) was added, and the mixture was stirred at room temperature for 5 hours. Water was added to the reaction solution, followed by extraction two times with ethyl acetate. The combined extracts were washed with water and saturated saline in this order and then dried over anhydrous magnesium sulfate. The solvent was distilled off, and the obtained oil was purified by silica gel column chromatography (n-hexane-ethyl acetate: 1:1→3:7, v/v) to obtain 7.90 g (yield: 66%) of compound 2C as an oil.
  • 1H-NMR (CDCl3) δ: 1.25 (3H, t, J=7.2 Hz), 2.95 (3H, br), 3.22 (3H, br), 4.15 (2H, q, J=7.2 Hz), 4.45 (2H, s), 4.59 (2H, s), 7.22-7.40 (5H, m), 7.73 (1H, s).
    • Step 3
  • Sodium tert-butoxide (495 mg, 5.15 mmol) and DMI (2 ml) were added to a three-neck flask in a nitrogen atmosphere, and a DMI (3 ml) solution of dimethyl oxalate (608 mg, 5.15 mmol) and compound 2C (0.50 g, 1.72 mmol) was added dropwise thereto at 25-30° C. After stirring at room temperature for 4 hours, 2 N hydrochloric acid (10 ml) was added, and the mixture was stirred at room temperature for 15 hours. After extraction two times with toluene, the combined extracts were washed with water, a saturated aqueous solution of sodium bicarbonate, water, and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 2:1, v/v) to obtain 420 mg (yield: 74%) of compound 2D as white crystals.
  • 1H-NMR (CDCl3) δ: 1.39 (3H, t, J=7.2 Hz), 3.88 (3H, s), 4.39 (2H, q, J=7.2 Hz), 5.34 (2H, s), 7.30-7.41 (3H, m), 7.45-7.50 (2H, m), 8.48 (1H, s).
    • Example 3
  • Figure US20140011995A1-20140109-C00113
    Figure US20140011995A1-20140109-C00114
    • Step 1
  • N,N-dimethylformamide dimethyl acetal (4.9 ml, 36.5 mmol) was added dropwise to compound 3A (5.0 g, 30.4 mmol) under cooling at 0° C. After stirring at 0° C. for 1 hour, 100 ml of ethyl acetate was added to the reaction solution, and the organic layer was washed with a 0.5 N aqueous hydrochloric acid solution (50 ml). The aqueous layer was separated, followed by extraction with ethyl acetate (50 ml). The organic layers were combined, washed with a saturated aqueous solution of sodium bicarbonate and saturated saline in this order, and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 1:1 (v/v)→ethyl acetate) to obtain 4.49 g (yield: 67%) of compound 3B as an oil.
  • 1H-NMR (CDCl3) δ: 1.32 (3H, t, J=7.1 Hz), 2.90 (3H, br s), 3.29 (3H, br s), 4.23 (2H, q, J=7.1 Hz), 4.54 (2H, s), 7.81 (1H, s).
    • Step 2
  • Lithium hexamethyldisilazide (1.0 M solution in toluene, 49 ml, 49.0 mmol) was diluted with tetrahydrofuran (44 ml). A tetrahydrofuran (10 ml) solution of compound 3B (4.49 g, 20.4 mmol) was added dropwise thereto under cooling at −78° C., and a tetrahydrofuran (10 ml) solution of ethyl oxalyl chloride (3.35 g, 24.5 mmol) was then added dropwise to the mixture. The mixture was stirred at −78° C. for 2 hours and then heated to 0° C. 2 N hydrochloric acid was added to the reaction solution, and the mixture was stirred for 20 minutes, followed by extraction with ethyl acetate (200 ml×2). The organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated saline and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 7:3→5:5→0:10 (v/v)) to obtain 1.77 g (yield: 31%) of compound 3C as a white solid.
  • 1H-NMR (CDCl3) δ: 1.36-1.46 (6H, m), 4.35-4.52 (8H, m), 8.53 (1H, s).
    • Step 3
  • Aminoacetaldehyde dimethyl acetal (0.13 ml, 1.20 mmol) was added to an ethanol (6 ml) solution of compound 3C (300 mg, 1.09 mmol) at 0° C., and the mixture was stirred at 0° C. for 1.5 hours, then at room temperature for 18 hours, and at 60° C. for 4 hours. The solvent in the reaction solution was distilled off under reduced pressure, and the obtained residue was then purified by silica gel column chromatography (n-hexane-ethyl acetate: 5:5→0:10 (v/v)) to obtain 252 mg (yield: 64%) of compound 3D as an oil.
  • 1H-NMR (CDCl3) δ: 1.36-1.47 (6H, m), 3.42 (6H, s), 3.90 (2H, d, J=5.2 Hz), 4.37 (3H, q, J=7.2 Hz), 4.50 (2H, q, J=7.2 Hz), 8.16 (1H, s).
    • Step 4
  • 62% H2SO4 (892 mg, 5.64 mmol) was added to a formic acid (10 ml) solution of compound 3D (1.02 g, 2.82 mmol), and the mixture was stirred at room temperature for 16 hours. The formic acid was distilled off under reduced pressure. To the residue, methylene chloride was added, and the mixture was pH-adjusted to 6.6 by the addition of a saturated aqueous solution of sodium bicarbonate. The methylene chloride layer was separated, while the aqueous layer was subjected to extraction with methylene chloride. The methylene chloride layers were combined and dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 531.8 mg of compound 3E as a yellow oil.
  • 1H-NMR (CDCl3) δ: 1.28-1.49 (6H, m), 4.27-4.56 (4H, m), 4.84 (2H, s), 8.10 (1H, s), 9.72 (1H, s).
    • Step 5
  • Methanol (0.20 ml, 5.0 mmol), (R)-3-amino-butan-1-ol (179 mg, 2.0 mmol), and acetic acid (0.096 ml, 1.70 mmol) were added to a toluene (5 ml) solution of compound 3E (531 mg, 1.68 mmol), and the mixture was heated to reflux for 4 hours. The reaction solution was cooled to room temperature, then diluted with chloroform, and then washed with a saturated aqueous solution of sodium bicarbonate. The aqueous layer was subjected to extraction with chloroform. The chloroform layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol: 100:0→90:10) to obtain 309.4 mg of compound 3F as a brown oil.
  • 1H-NMR (CDCl3) δ: 1.40 (3H, t, J=7.1 Hz), 1.40 (3H, d, J=7.1 Hz), 1.55-1.61 (1H, m), 2.19-2.27 (1H, m), 4.00 (1H, d, J=1.5 Hz), 4.03 (1H, d, J=2.5 Hz), 4.10 (1H, dd, J=13.2, 6.3 Hz), 4.26 (1H, dd, J=13.2, 3.8 Hz), 4.38 (2H, q, J=7.1 Hz), 5.00-5.05 (1H, m), 5.31 (1H, dd, J=6.4, 3.9 Hz), 8.10 (1H, s).
    • Step 6
  • Potassium trimethylsilanolate (333 mg, 2.34 mmol) was added to a 1,2-dimethoxyethane (2 ml) solution of compound 3F (159 mg, 0.47 mmol), and the mixture was stirred at room temperature for 7 hours. 1 N hydrochloric acid and saturated saline were added to the reaction solution, followed by extraction with chloroform. The chloroform layers were combined and dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 34.4 mg (yield: 25%) of compound 3G as an orange powder.
  • 1H-NMR (CDCl3) δ: 1.46 (3H, d, J=3.5 Hz), 1.58-1.65 (1H, m), 2.26-2.30 (1H, m), 4.06-4.10 (2H, m), 4.31 (1H, dd, J=13.8, 5.6 Hz), 4.48 (1H, dd, J=13.6, 3.9 Hz), 5.03 (1H, t, J=6.4 Hz), 5.36 (1H, dd, J=5.5, 4.0 Hz), 8.44 (1H, s), 12.80 (1H, s), 14.90 (1H, s).
    • Step 7
  • Compound 3G (16 mg, 0.054 mmol) and 2,4-difluorobenzylamine (17 mg, 0.12 mmol) were dissolved in N,N-dimethylformamide (1 ml). To the solution, N,N,N′,N′-tetramethyl-O-(7-aza-benzotriazol-1-yl)uronium hexafluorophosphate (HATU) (53 mg, 0.14 mmol) and N-methylmorpholine (0.031 ml, 0.28 mmol) were added, and the mixture was stirred at room temperature for 16 hours. 2,4-difluorobenzylamine (17 mg, 0.12 mmol), HATU (64 mg, 0.17 mmol), and N-methylmorpholine (0.037 ml, 0.34 mmol) were further added thereto, and the mixture was stirred at room temperature for additional 16 hours. 0.5 N hydrochloric acid was added to the reaction solution, followed by extraction with ethyl acetate. The ethyl acetate layers were combined, washed with 0.5 N hydrochloric acid and then with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by preparative high-performance liquid chromatography to obtain 12.5 mg (yield: 55%) of compound 3H as an orange solid.
  • 1H-NMR (DMSO-d6) δ: 1.36 (3H, d, J=6.9 Hz), 1.55-1.60 (1H, m), 2.01-2.05 (1H, m), 3.92-3.94 (1H, m), 4.04 (1H, t, J=12.6 Hz), 4.38-4.41 (1H, m), 4.57-4.60 (1H, m), 4.81-4.83 (1H, m), 5.46-5.49 (1H, m), 7.08-7.11 (1H, m), 7.25-7.30 (1H, m), 7.41 (1H, dd, J=15.3, 8.7 Hz), 8.53 (1H, s), 10.38 (1H, s), 12.53 (1H, s).
    • Example 4
  • Figure US20140011995A1-20140109-C00115
    Figure US20140011995A1-20140109-C00116
    • Step 1
  • N,N-dimethylformamide dimethyl acetal (12.2 ml, 92.2 mmol) was added dropwise to compound 4A (10.0 g, 76.8 mmol) under cooling at 0° C. After stirring at 0° C. for 1.5 hours and then at room temperature for 2.5 hours, 100 ml of ethyl acetate was added to the reaction solution, and the solvent was distilled off. The obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 5:5→0:10 (v/v)) to obtain 12.45 g (yield: 88%) of compound 4B as an oil.
  • 1H-NMR (CDCl3) δ: 1.32 (3H, t, J=7.1 Hz), 2.33 (3H, s), 3.04 (6H, br s), 4.23 (2H, q, J=7.2 Hz), 7.68 (1H, s).
    • Step 2
  • Lithium hexamethyldisilazide (1.0 M solution in toluene, 24 ml, 24.0 mmol) was diluted with tetrahydrofuran (20 ml). A tetrahydrofuran (5 ml) solution of compound 4B (1.85 g, 10.0 mmol) was added dropwise thereto under cooling at −78° C., and a tetrahydrofuran (5 ml) solution of ethyl oxalyl chloride (1.34 ml, 12.0 mmol) was then added dropwise thereto. After stirring at −78° C. for 2 hours, 2 N hydrochloric acid was added to the reaction solution, and the mixture was stirred at room temperature for 20 minutes. After extraction with ethyl acetate, the organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 75:25→455:5 (v/v)) to obtain 1.03 g (yield: 43%) of compound 4C as a brown oil.
  • 1H-NMR (CDCl3) δ: 1.38 (3H, t, J=7.1 Hz), 1.42 (3H, t, J=7.4 Hz), 4.33-4.47 (4H, m), 7.19 (1H, s), 8.54 (1H, s).
    • Step 3
  • Aminoacetaldehyde dimethyl acetal (0.34 ml, 3.11 mmol) was added to an ethanol (6.8 ml) solution of compound 4C (680 mg, 2.83 mmol) at 0° C., and the mixture was left standing at room temperature for 16 hours. The solvent in the reaction solution was distilled off under reduced pressure, and the obtained residue was then purified by silica gel column chromatography (n-hexane-ethyl acetate: 90:10 (v/v)) to obtain 875 mg (yield: 94%) of compound 4D as an oil.
  • 1H-NMR (CDCl3) δ: 1.38 (3H, t, J=7.1 Hz), 1.39 (3H, t, J=7.1 Hz), 3.40 (6H, s), 4.33 (2H, d, J=4.7 Hz), 4.37 (4H, q, J=7.1 Hz), 4.49 (1H, t, J=4.7 Hz), 7.06 (1H, s), 8.17 (1H, s).
    • Step 4
  • N-bromosuccinimide (1.46 g, 8.18 mmol) was added to a N,N-dimethylformamide (10 ml) solution of compound 4D (2.68 g, 8.18 mmol), and the mixture was stirred at room temperature for 48 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was then purified by silica gel column chromatography (n-hexane-ethyl acetate: 90:10 (v/v)) to obtain 2.83 g (yield: 85%) of compound 4E as an oil.
  • 1H-NMR (CDCl3) δ: 1.41 (3H, t, J=7.1 Hz), 1.48 (3H, t, J=7.1 Hz), 3.42 (6H, s), 3.90 (2H, d, J=5.0 Hz), 4.39 (2H, q, J=7.1 Hz), 4.53 (3H, q, J=14.3 Hz), 4.54 (3H, s), 4.57 (3H, t, J=5.4 Hz), 8.19 (1H, s).
    • Step 5
  • 62% H2SO4 (1.74 g, 10.98 mmol) was added to a formic acid (15 ml) solution of compound 4E (2.23 g, 5.49 mmol), and the mixture was stirred at room temperature for 8 hours. A 0.5 N aqueous sodium hydroxide solution (120 ml) was added thereto, followed by extraction with methylene chloride. The methylene chloride layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 1.31 g of compound 4F as a white powder.
  • 1H-NMR (CDCl3) δ: 1.31-1.46 (6H, m), 4.33-4.48 (4H, m), 4.82 (2H, s), 8.11 (1H, s), 9.71 (1H, s).
    • Step 6
  • Methanol (0.44 ml, 10.9 mmol), (R)-3-amino-butan-1-ol (389 mg, 4.36 mmol), and acetic acid (0.21 ml, 3.64 mmol) were added to a toluene (13 ml) solution of compound 4F (1.31 g, 3.64 mmol), and the mixture was heated to reflux for 3 hours. The reaction solution was cooled to room temperature, then diluted with chloroform, and then washed with a saturated aqueous solution of sodium bicarbonate. The aqueous layer was subjected to extraction with chloroform. The chloroform layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol: 100:0→90:10) to obtain 1.58 g of compound 4G as an oil.
  • 1H-NMR (CDCl3) δ: 1.40 (3H, d, J=5.7 Hz), 1.56-1.60 (1H, m), 2.19-2.24 (1H, m), 3.99 (1H, d, J=2.0 Hz), 4.02 (1H, d, J=2.4 Hz), 4.11 (1H, dd, J=13.3, 6.7 Hz), 4.28 (1H, dd, J=13.3, 3.9 Hz), 4.36 (3H, q, J=7.1 Hz), 4.49-4.56 (1H, m), 4.98-5.03 (1H, m), 5.34 (1H, dd, J=6.6, 3.8 Hz), 8.07 (1H, s).
    • Step 7
  • Potassium trimethylsilanolate (249 mg, 1.95 mmol) was added to a 1,2-dimethoxyethane (3 ml) solution of compound 4G (300 mg, 0.78 mmol), and the mixture was stirred at room temperature for 1 hour. Potassium trimethylsilanolate (249 mg, 1.95 mmol) was further added thereto, and the mixture was stirred at 60° C. for additional 1 hour. 1 N hydrochloric acid and saturated saline were added to the reaction solution, followed by extraction with chloroform. The chloroform layers were combined and dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 100.3 mg (yield: 43%) of compound 3G as a yellow powder.
  • 1H-NMR (CDCl3) δ: 1.46 (3H, d, J=3.5 Hz), 1.58-1.65 (1H, m), 2.26-2.30 (1H, m), 4.06-4.10 (2H, m), 4.31 (1H, dd, J=13.8, 5.6 Hz), 4.48 (1H, dd, J=13.6, 3.9 Hz), 5.03 (1H, t, J=6.4 Hz), 5.36 (1H, dd, J=5.5, 4.0 Hz), 8.44 (1H, s), 12.80 (1H, s), 14.90 (1H, s).
    • Example 5
  • Figure US20140011995A1-20140109-C00117
    • Step 1
  • Compound 5A (598 mg, 4.09 mmol) and N,N-dimethylformamide dimethyl acetal (488 mg, 4.09 mmol) were dissolved in toluene (1 ml), and the solution was stirred at room temperature for 11 hours. The solvent in the reaction solution was distilled off under reduced pressure, and the obtained residue (containing compound 5B) was used in Step 2 without being purified.
    • Step 2
  • Sodium tert-butoxide (400 mg, 4.16 mmol) was suspended in dimethylimidazolidinone (5 ml). To this suspension, a dimethylimidazolidinone (5 ml) solution of the crude product obtained in Step 1 was added. Then, a THF (10 ml) solution of dimethyl oxalate (983 mg, 8.32 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 45 minutes. The reaction solution was added to 2 N hydrochloric acid-methanol (20 ml), and the mixture was stirred at 0° C. for 20 minutes. Water was added thereto, followed by extraction with ethyl acetate. The organic layer was washed with water, a saturated aqueous solution of sodium bicarbonate, and saturated saline in this order and dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was then purified by silica gel column chromatography to obtain 222 mg (yield based on compound 5A: 22%) of compound 5C.
  • 1H-NMR (CDCl3) δ: 3.91 (3H, s), 3.97 (3H, s), 4.05 (3H, s), 8.50 (1H, s).
    • Example 6
  • Figure US20140011995A1-20140109-C00118
    • Step 1
  • Lithium hexamethyldisilazide (1.0 M solution in toluene, 12 ml, 12.0 mmol) was diluted with tetrahydrofuran (11 ml). A tetrahydrofuran (2 ml) solution of compound 6A (1.46 g, 5.0 mmol) was added dropwise thereto under cooling at −78° C., and a tetrahydrofuran (2 ml) solution of ethyl oxalyl chloride (0.67 ml, 6.0 mmol) was then added dropwise thereto. After stirring at −78° C. for 2 hours, ammonium acetate (500 mg) and acetic acid (10 ml) were added to the reaction solution, and the mixture was stirred at 65° C. for 1.5 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and a saturated aqueous solution of sodium bicarbonate in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 55:45→45:55 (v/v)) to obtain 505.1 mg of compound 6B as a yellow solid. This solid was washed with isopropyl ether-hexane (1:2) and dried under reduced pressure to obtain 416.8 mg (yield: 24%) of compound 6B as yellow crystals.
  • 1H-NMR (CDCl3) δ: 1.35 (3H, t, J=7.1 Hz), 1.46 (3H, t, J=7.1 Hz), 4.40 (2H, q, J=7.2 Hz), 4.50 (2H, q, J=7.1 Hz), 5.20 (2H, s), 7.33-7.41 (3H, m), 7.49-7.52 (2H, m), 8.76 (1H, s), 11.61 (1H, br s).
    • Step 2
  • Cesium carbonate (73.3 mg, 0.23 mmol) and bromoacetaldehyde dimethyl acetal (38.0 mg, 0.23 mmol) were added to a N,N-dimethylformamide (1 ml) solution of compound 6B (51.8 mg, 0.15 mmol), and the mixture was stirred overnight at room temperature. Cesium carbonate (73.3 mg, 0.23 mmol) and bromoacetaldehyde dimethyl acetal (38.0 mg, 0.23 mmol) were further added thereto, and the mixture was stirred at 100° C. for additional 20 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated saline in this order and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 50:50→30:70 (v/v)) to obtain 35.3 mg (yield: 54%) of compound 6C as a colorless oil.
  • 1H-NMR (CDCl3) δ: 1.26 (3H, t, J=7.1 Hz), 1.40 (3H, t, J=7.1 Hz), 3.39 (6H, s), 3.91 (2H, d, J=5.0 Hz), 4.29 (2H, q, J=7.1 Hz), 4.40 (2H, q, J=7.2 Hz), 4.50 (1H, t, J=5.0 Hz), 5.30 (2H, s), 7.31-7.37 (3H, m), 7.43-7.46 (2H, m), 8.12 (1H, s).
    • Example 7
  • Figure US20140011995A1-20140109-C00119
    • Step 1
  • Compound 6A (291 mg, 1.0 mmol) and dimethyl oxalate (354 mg, 3.0 mmol) were dissolved in dimethylimidazolidinone (1.4 ml). To this solution, sodium methoxide (28% solution in methanol, 0.30 ml, 1.5 mmol) was added, and the mixture was stirred at room temperature for 2 hours. 1,3-dioxolan-2-yl-methylamine (154 mg, 1.5 mmol) and acetic acid (0.29 ml, 5.0 mmol) were added thereto, and the mixture was stirred at room temperature for 38 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The ethyl acetate layers were combined, washed with water and saturated saline in this order, and dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate: 33:67→15:85) to obtain 294.8 mg (yield: 70%) of compound 6C′ as a pale yellow oil.
  • 1H-NMR (CDCl3) δ: 1.43 (3H, t, J=7.1 Hz), 3.73-3.75 (2H, m), 3.81 (3H, s), 3.82-3.85 (2H, m), 4.21 (2H, d, J=2.2 Hz), 4.42 (2H, q, J=7.1 Hz), 5.14 (1H, t, J=2.3 Hz), 5.32 (2H, s), 7.34-7.37 (3H, m), 7.44-7.46 (2H, m), 8.14 (1H, s).
    • Example 8
  • Figure US20140011995A1-20140109-C00120
    • Step 1
  • Aminoacetaldehyde dimethyl acetal (7.80 mmol) was added to an ethanol (5 ml) solution of compound 8A (900 mg, 2.60 mmol), and the mixture was stirred at room temperature for 22 hours. Ethyl acetate (5 ml) and water (5 ml) were added to the reaction solution, followed by extraction with ethyl acetate (5 ml). The organic layer was washed with water (10 ml). Then, the solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 2:1) to obtain 0.37 g (yield: 33%) of compound 6C as a colorless oil.
  • 1H-NMR (CDCl3) δ: 7.90 (1H, s), 7.45-7.43 (5H, m), 5.30 (2H, s), 4.51 (1H, t, J=5.1 Hz), 4.40 (2H, q, J=7.1 Hz), 4.30 (2H, q, J=7.1 Hz), 3.91 (2H, d, J=5.1 Hz), 3.46 (6H, s), 1.40 (3H, t, J=7.1 Hz), 1.26 (3H, t, J=7.1 Hz).
    • Step 2
  • 62% H2SO4 (316 mg, 2.0 mmol) was added to a formic acid (4 ml) solution of compound 6C (433.5 mg, 1.0 mmol), and the mixture was stirred at room temperature for 3 hours. Methylene chloride was added to the reaction solution, and the organic layer was washed with a 0.5 N aqueous sodium hydroxide solution (12 ml). The aqueous layer was subjected to extraction with methylene chloride. The methylene chloride layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 207.6 mg (yield: 51%) of compound 8C as a yellow foam.
  • 1H-NMR (CDCl3) δ: 1.23 (3H, t, J=7.1 Hz), 1.42 (3H, t, J=7.1 Hz), 4.25 (2H, q, J=7.2 Hz), 4.42 (2H, q, J=7.1 Hz), 4.79 (2H, s), 5.34 (2H, s), 7.31-7.53 (5H, m), 8.05 (1H, s), 9.67 (1H, s).
    • Step 3
  • Methanol (0.061 ml, 1.5 mmol), (R)-3-amino-butan-1-ol (53.5 mg, 0.60 mmol), and acetic acid (0.029 ml, 0.50 mmol) were added to a toluene (2 ml) solution of compound 8C (202.6 mg, 0.50 mmol), and the mixture was heated to reflux for 3 hours. The reaction solution was cooled to room temperature. Then, methylene chloride was added thereto, and the organic layer was washed with a saturated aqueous solution of sodium bicarbonate. The aqueous layer was subjected to extraction with methylene chloride. The methylene chloride layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol: 100:0→91:9) to obtain 161.6 mg (yield: 78%) of compound 8D as a yellow foam.
  • 1H-NMR (CDCl3) δ: 1.34 (3H, d, J=7.1 Hz), 1.41 (3H, t, J=7.1 Hz), 1.49-1.54 (1H, m), 2.14-2.20 (1H, m), 3.96-3.97 (2H, m), 4.03 (3H, dd, J=13.3, 5.9 Hz), 4.17 (3H, dd, J=13.3, 3.7 Hz), 4.41 (3H, q, J=7.1 Hz), 5.01 (1H, t, J=5.6 Hz), 5.17 (1H, dd, J=5.9, 3.9 Hz), 5.33 (2H, d, J=10.1 Hz), 5.39 (2H, d, J=9.9 Hz), 7.33-7.36 (3H, m), 7.68-7.70 (2H, m), 8.05 (1H, s).
    • Step 4
  • Compound 8D (50 mg, 0.12 mmol) was dissolved in tetrahydrofuran-methanol (0.5 ml and 0.5 ml, respectively). To this solution, a 1 N aqueous sodium hydroxide solution (0.36 ml, 0.36 mmol) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was pH-adjusted to 2.5 by the addition of 1 N hydrochloric acid and subjected to extraction with chloroform. The chloroform layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off to obtain 46.2 mg (yield: 99%) of compound 8E as a pale yellow foam.
  • 1H-NMR (CDCl3) δ: 1.38 (3H, d, J=7.1 Hz), 1.53-1.56 (1H, m), 2.16-2.18 (1H, m), 3.98-3.99 (2H, m), 4.17 (1H, dd, J=13.3, 5.9 Hz), 4.29 (1H, dd, J=13.4, 3.5 Hz), 5.02 (1H, t, J=6.6 Hz), 5.21 (1H, dd, J=5.5, 3.9 Hz), 5.40 (1H, d, J=10.2 Hz), 5.45 (1H, d, J=10.1 Hz), 7.34-7.39 (3H, m), 7.60-7.62 (2H, m), 8.33 (1H, s), 15.02 (1H, s).
    • Step 5
  • Compound 8E (50 mg, 0.13 mmol) and 2,4-difluorobenzylamine (20.5 mg, 0.14 mmol) were dissolved in N,N-dimethylformamide (1 ml). To the solution, N,N,N′,N′-tetramethyl-O-(7-aza-benzotriazol-1-yl)uronium hexafluorophosphate (HATU) (64 mg, 0.17 mmol) and N-methylmorpholine (0.037 ml, 0.34 mmol) were added, and the mixture was stirred at room temperature for 16 hours. HATU (64 mg, 0.17 mmol) and N-methylmorpholine (0.037 ml, 0.34 mmol) were further added thereto, and the mixture was stirred at room temperature for additional 16 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The ethyl acetate layers were combined, washed with saturated saline, and then dried over anhydrous sodium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol: 100:0→95:5) to obtain 48.4 mg (yield: 73%) of compound 8F as a yellow oil.
  • 1H-NMR (CDCl3) δ: 1.36 (4H, d, J=7.1 Hz), 1.50-1.55 (1H, m), 2.16-2.18 (1H, m), 3.98-3.99 (2H, m), 4.11 (1H, dd, J=13.4, 6.0 Hz), 4.24 (1H, dd, J=13.5, 3.9 Hz), 4.66 (2H, d, J=5.9 Hz), 5.01-5.04 (1H, m), 5.19 (1H, dd, J=6.0, 3.9 Hz), 5.29 (1H, d, J=10.2 Hz), 5.33 (1H, d, J=9.9 Hz), 6.79-6.87 (2H, m), 7.31-7.43 (4H, m), 7.63-7.65 (2H, m), 8.36 (1H, s), 10.42 (1H, s).
    • Example 9
  • Figure US20140011995A1-20140109-C00121
    • Step 1
  • In a two-neck flask, compound 9C (291.3 mg, 10 mmol) was dissolved in DMI (1.4 mL) in a nitrogen atmosphere. To the solution, dimethyl oxalate (354.3 mg, 3.0 mmol) and sodium methoxide (28% solution in methanol 0.3 mL, 1.5 mmol) was added, and the mixture was stirred at room temperature for 2 hours. 2-(aminomethyl)-1,3-dioxane (154.7 mg, 1.5 mmol) and acetic acid (0.29 mL, 5.0 mmol) were added thereto, and the mixture was stirred at room temperature for 5 hours. Ethyl acetate (50 mL) was added to the reaction solution, and the organic layer was washed with water (20 mL), a 10% aqueous ammonium chloride solution (20 mL), water (20 mL), and saturated saline (20 mL) in this order and dried over anhydrous magnesium sulfate. The solvent was distilled off, and the obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate: 1:1→1:3, v/v) to obtain 99.0 mg (yield: 25%) of compound 9C′ as white crystals.
  • 1H-NMR (CDCl3) δ: 8.14 (1H, s), 7.44-7.42 (5H, m), 5.29 (2H, s), 5.12 (1H, s), 4.19 (2H, s), 3.93 (3H, s), 3.83-3.70 (2H, m), 3.83 (2H, s).
    • Example 10
  • Figure US20140011995A1-20140109-C00122
    • Step 1
  • Compound 10A (944 mg, 2.33 mmol) was mixed with 2,4-difluorobenzyl amine (401 mg, 2.80 mmol). To the mixture, methanol (2 mL) was added, and the mixture was stirred at 60° C. for 1 hour and then at 95° C. for 1.5 hours. 2,4-difluorobenzyl amine (401 mg, 2.80 mmol) was further added thereto, and the mixture was stirred at 95° C. for additional 3 hours. A 10% aqueous citric acid solution was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated saline and dried over anhydrous magnesium sulfate. The solvent was distilled off, and the obtained residue was then purified by silica gel column chromatography to obtain 310 mg (yield: 25%) of compound 10B.
  • 1H-NMR (CDCl3) δ: 3.41 (6H, s), 3.82 (3H, s), 4.04 (2H, d, J=4.9 Hz), 4.49 (1H, t, J=4.9 Hz), 4.67 (2H, d, J=5.9 Hz), 5.28 (2H, s), 6.79-6.89 (2H, m), 7.29-7.46 (5H, m), 8.44 (1H, s), 10.45 (1H, t, J=5.5 Hz).
  • The acetal moiety of the compound 10B obtained in Example 10 is converted to an aldehyde group in the same way as in Step 4 of Example 3. The resulting compound is reacted with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol. The benzyl group, which is an alcohol protective group, can be subjected to deprotection reaction (using, for example, Pd—C/H2 gas) to induce the compound (Y1) or (Y2) of interest.
    • Example 11
  • Figure US20140011995A1-20140109-C00123
    • Step 1
  • A dichloromethane (90 mL) solution of compound 11A (12.8 g, 89.4 mmol) and pyridine (8.50 g, 107 mmol) was cooled to 1-3° C., and a dichloromethane (90 mL) solution of benzyloxy acetyl chloride (19.8 g, 107 mmol) was added dropwise thereto over 50 minutes with the same temperature kept. The reaction solution was stirred at the same temperature for 30 minutes and then gradually heated to 15° C. over 60 minutes, and ice water was added thereto. The dichloromethane layer was separated, while the aqueous layer was subjected to extraction once with dichloromethane. The combined extracts were washed with water three times, and washed with saturated saline, and then dried. The solvent was distilled off, and the obtained oil was subjected to silica gel column chromatography for purification. Elution was performed first with n-hexane and then with n-hexane-ethyl acetate (1:1, v/v). The fraction of interest was concentrated to obtain 22.2 g of compound 11B as an oil.
  • 1H-NMR (CDCl3) δ: 1.25 (3H, t, J=7.2 Hz), 2.90 (3H, brs), 3.24 (3H, brs), 4.15 (2H, q, J=7.2 Hz), 4.45 (2H, s), 4.58 (2H, s), 7.25-7.38 (5H, m), 7.72 (1H, s).
  • The compound 11B obtained in Example 11 can be used in the next reaction in the same way as in Example 6.
    • Example 12
  • Figure US20140011995A1-20140109-C00124
    • Step 1
  • Aminoacetaldehyde dimethyl acetal (0.72 g, 6.9 mmol) was added dropwise to a methanol (20 mL) slurry solution of Compound 12A (2.0 g, 6.3 mmol) at room temperature, and the mixture was then stirred for 6 hours under heating to reflux. After the completion of reaction, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:17 (v/v)) to obtain 2.26 g (yield: 88%) of compound 12B as a colorless oil.
  • 1H-NMR (CDCl3) δ: 3.38 (6H, s), 3.81 (3H, s), 3.91 (2H, d, J=4.7 Hz), 3.93 (3H, s), 4.47 (1H, t, J=4.7 Hz), 5.29 (2H, s), 7.29-7.37 (3H, m), 7.42-7.44 (2H, m), 8.15 (1H, s).
  • The compound 12B was dried under conditions of concentration under reduced pressure and left standing at 5° C. for approximately 2 months. In this case, this compound was still in an oil form and was not crystallized. As a result of various studies, however, the compound was successfully crystallized by repeating the addition of ethyl acetate and concentration and isolated as white crystals.
    • Step 2
  • A 62% aqueous sulfuric acid solution (307 mg, 1.9 mmol) was added dropwise to a formic acid (3.7 mL) solution of compound 12B (525 mg, 1.3 mmol) at room temperature, and the mixture was stirred at the same temperature for 3 hours. After the completion of reaction, the solution was cooled to 5° C. and neutralized by the addition of a saturated aqueous solution of sodium bicarbonate (24.5 g), followed by extraction with dichloromethane (5 mL×4). The solvent was distilled off under reduced pressure. Then, toluene (5.2 mL) was added to the obtained residue, and methanol (125 mg, 3.9 mmol), (R)-3-amino-butan-1-ol (127 mg, 1.4 mmol), and acetic acid (78 mg, 1.4 mmol) were further added dropwise thereto in this order at room temperature. The mixture was heated to 90° C., stirred for 3 hours, and then allowed to cool to room temperature. Then, water (2 mL) was added thereto, followed by extraction with ethyl acetate (10 mL×2). The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (chloroform:methanol=97:3 (v/v)) to obtain 418 mg (yield: 81%) of compound 12C as a white foam.
  • 1H-NMR (CDCl3) δ: 1.33 (3H, d, J=7.1 Hz), 1.50 (2H, dd, J=13.9, 2.3 Hz), 2.11-2.20 (1H, m), 3.93 (3H, s), 3.94 (1H, d, J=2.5 Hz), 3.96 (1H, br s), 4.02 (1H, dd, J=13.4, 5.8 Hz), 4.15 (1H, dd, J=13.4, 3.8 Hz), 5.04-4.96 (1H, m), 5.16 (1H, dd, J=6.1, 4.1 Hz), 5.35 (2H, dd, J=22.8, 10.1 Hz), 7.28-7.36 (3H, m), 7.67 (2H, d, J=7.1 Hz), 8.07 (1H, s).
    • Step 3
  • 2,4-difluorobenzylamine (75 mg, 0.52 mmol) and acetic acid (31 mg, 0.52 mmol) were added dropwise to a toluene (3.4 mL) slurry solution of compound 12C (171 mg, 0.43 mmol) at room temperature, and the mixture was then heated to 100° C. and stirred for 7 hours. After the completion of reaction, the solvent was distilled off under reduced pressure, and the obtained residue was then purified by silica gel chromatography (chloroform:methanol=97:3 (v/v)) to obtain 150 mg (yield: 69%) of compound 12D as yellow crystals.
    • Example 13
  • Figure US20140011995A1-20140109-C00125
    • Step 1
  • 2,4-difluorobenzylamine (209 mg, 1.4 mmol) and acetic acid (88 mg, 1.4 mmol) were added to a toluene (5.4 mL) suspension of compound 12B (539 mg, 1.3 mmol) at room temperature, and the mixture was then heated to 90° C. and stirred for 7 hours. After the completion of reaction, the solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel chromatography (n-hexane:ethyl acetate=3:7 (v/v)) to obtain 666 mg (yield: 97%) of compound 13C as a pale yellow oil.
  • 1H-NMR (CDCl3) δ: 3.37 (6H, s), 3.79 (3H, s), 4.01 (2H, d, J=5.0 Hz), 4.47 (1H, t, J=5.0 Hz), 4.65 (2H, d, J=6.0 Hz), 5.26 (2H, s), 6.78-6.86 (2H, m), 7.30-7.42 (6H, m), 8.42 (1H, s), 10.41 (1H, t, J=6.0 Hz).
    • Step 2
  • A 62% aqueous sulfuric acid solution (306 mg, 1.9 mmol) was added to a toluene (2.7 mL)-formic acid (6.7 mL) solution of compound 13C (666 mg, 1.3 mmol) at room temperature, and the mixture was stirred at the same temperature for 3 hours. After the completion of reaction, the solution was cooled to 5° C. and neutralized by the addition of a saturated aqueous solution of sodium bicarbonate (37.0 g), followed by extraction with ethyl acetate (10 mL×2). The solvent was distilled off under reduced pressure. Then, toluene (6.7 mL) was added to the obtained residue, and methanol (124 mg, 3.9 mmol), (R)-3-amino-butan-1-ol (138 mg, 1.6 mmol), and acetic acid (85 mg, 1.4 mmol) were further added dropwise thereto in this order at room temperature. The mixture was heated to 90° C., stirred for 2 hours, and then allowed to cool to room temperature. Then, water (7 mL) was added thereto, followed by extraction with ethyl acetate (10 mL×2). The solvent was distilled off under reduced pressure, and toluene was added to the residue. Then, the solvent was distilled off under reduced pressure to bring the contents to approximately 4.0 g. The residue was concentrated and crystallized. The obtained yellow slurry solution was filtered to obtain 429 mg (yield: 65%) of compound 12D as pale yellow crystals.
    • Example 14
  • Figure US20140011995A1-20140109-C00126
    • Step 1
  • Water (2.5 mL) and aminoacetaldehyde dimethyl acetal (756 μL, 7.0 mmol) were added to compound 14A (1.0 g, 7.1 mmol) at room temperature. The mixture was stirred at 65° C. for 1.5 hours and then stirred at 100° C. for 3.5 hours. After concentration to dryness, crystals were deposited by the addition of water (5 mL). 2-propanol (10 mL) was added thereto, followed by filtration. The crystals were washed with 2-propanol (5 mL) and through-flow-dried to obtain 0.98 g (yield: 76%) of crystals of compound 14B.
  • 1H-NMR (CDCl3) δ: 4.56 (2H, d, J=4.9 Hz), 5.38 (1H, t, J=4.9 Hz), 7.16 (1H, dd, J=7.3 Hz, 2.9 Hz), 7.26 (1H, d, J=2.9 Hz), 8.31 (1H, d, J=7.3 Hz).
    • Step 2
  • (R)-3-amino-butan-1-ol (75.1 mg, 0.82 mmol) was diluted with 2-propanol (1 mL), and compound 14B (100.6 mg, 0.56 mmol) was added thereto. To the mixture, acetic acid (50 μl) was added, and the mixture was stirred at 80° C. for 16 hours. The solvent was distilled off, and the obtained residue was purified by reverse-phase column chromatography (water-acetonitrile: 95:5→70:30 (v/v)) to obtain 42.0 mg (yield: 32%) of compound 14C as an oil.
  • 1H-NMR (CDCl3) δ: 1.31 (3H, d, J=7.0 Hz), 1.49 (1H, m), 1.96 (1H, m), 3.87 (1H, ddd, J=11.6 Hz, 5.1 Hz, 2.3 Hz), 4.01 (1H, m), 4.12 (1H, dd, J=13.6 Hz, 4.9 Hz), 4.33 (1H, dd, J=13.6 Hz, 4.0 Hz), 4.79 (1H, m), 5.40 (1H, dd, J=4.9 Hz, 4.0 Hz), 6.23 (1H, d, J=7.4 Hz, 2.9 Hz), 6.77 (1H, d, J=2.9 Hz), 7.72 (1H, d, J=7.4 Hz).
    • Step 3
  • An acetonitrile (1.5 mL) solution of NBS (191.4 mg, 1.08 mmol) was added dropwise to an acetonitrile (1.5 mL) solution of compound 14C (100.0 mg, 0.43 mmol) at room temperature, and the mixture was stirred at room temperature for 21 hours (including 30 min at 40° C.). Then, NBS (50.1 mg, 0.28 mmol) was further added thereto. After stirring at room temperature for 2 hours, the solvent was distilled off. The obtained residue was purified by reverse-phase column chromatography (water-acetonitrile: 95:5→40:60 (v/v)) to obtain 30.2 mg (yield: 18%) of compound 14D as crystals.
  • 1H-NMR (CDCl3) δ: 1.27 (3H, d, J=7.0 Hz), 1.53 (1H, m), 1.96 (1H, m), 3.87 (1H, m), 3.95 (1H, m), 4.22 (1H, dd, J=13.5 Hz, 6.2 Hz), 4.45 (1H, dd, J=13.5 Hz, 3.8 Hz), 4.74 (1H, m), 5.37 (1H, dd, J=6.2 Hz, 3.8 Hz), 8.50 (1H, s).
    • Step 4
  • A 1 mol/L solution of sodium benzyloxide in benzyl alcohol (100 μL, 0.1 mmol) was added to a benzyl alcohol (0.5 mL) solution of compound 14D (5.11 mg, 0.013 mmol) at room temperature, and the mixture was stirred at 90° C. for 50 minutes. The obtained reaction solution was purified by reverse-phase column chromatography (water-acetonitrile: 95:5->40:60 (v/v)) to obtain 2.98 mg (yield: 55%) of compound 14E as crystals.
  • 1H-NMR (CDCl3) δ: 1.27 (3H, d, J=7.0 Hz), 1.59 (1H, m), 1.93 (1H, m), 3.84 (1H, m), 3.96 (1H, m), 4.18 (1H, dd, J=13.5 Hz, 5.5 Hz), 4.39 (1H, dd, J=13.5 Hz, 4.0 Hz), 4.77 (1H, m), 5.04 (2H, s), 5.32 (1H, dd, J=5.5 Hz, 3.5 Hz), 7.31 (1H, m), 7.39 (2H, m), 7.56 (2H, m), 8.38 (1H, s).
    • Example 15A Obtainment of Crystals 15A of Anhydride by Crystallization of Compound 12C
  • Figure US20140011995A1-20140109-C00127
  • An ethyl acetate (3 mL) solution of hydroquinone (168 mg, 1.52 mmol) was added dropwise to an ethyl acetate (4 mL) solution of compound 12C (1.01 g, 2.53 mmol) at room temperature. After stirring at the same temperature for 1 hour, the obtained slurry solution was filtered to obtain 0.95 g (yield: 81%) of compound 15A as pale yellow crystals. The compound 15A was confirmed to be hydroquinone hemisolvate crystals of compound 12C.
  • 1H-NMR (CDCl3) δ: 1.32 (3H, d, J=7.1 Hz), 1.50 (1H, dd, J=14.2, 2.0 Hz), 2.16 (1H, ddd, J=21.8, 8.1, 5.8 Hz), 3.93 (3H, s), 3.94-3.97 (2H, m), 4.02 (1H, dd, J=13.2, 6.1 Hz), 4.15 (1H, dd, J=13.2, 3.5 Hz), 4.58 (1H, br s), 5.00 (1H, td, J=6.7, 2.2 Hz), 5.16 (1H, dd, J=6.1, 3.5 Hz), 5.34 (2H, dd, J=22.8, 10.1 Hz), 6.72 (1H, s), 7.32 (3H, dt, J=18.9, 5.4 Hz), 7.66 (2H, d, J=7.1 Hz), 8.07 (1H, s).
    • Example 15B Obtainment of Crystals 15B of Hydrate by Crystallization of Compound 15A
  • Figure US20140011995A1-20140109-C00128
  • Water (500 μl) was added to compound 15A (50 mg) at room temperature, and the mixture was stirred at the same temperature for 1 hour and then stirred at 70° C. for 2 hours. Then, the obtained slurry solution was filtered to obtain compound 15B as pale yellow crystals. The compound 15B was confirmed to be hemihydrate and hydroquinone hemisolvate crystals of compound 12C.
    • Example 16 Measurement of Powder X-Ray Diffraction Pattern
  • The powder X-ray diffractometry of the crystals obtained in each Example was performed under the following measurement conditions according to the powder X-ray diffractometry described in the general test methods of the Japanese Pharmacopoeia.
    • (Apparatus)
  • D-8 Discover manufactured by Bruker Corp.
    • (Operation Procedure)
  • Each sample was assayed under the following conditions:
  • Measurement method: Reflection method
    Type of light source: Cu tube
    Wavelength used: CuKα rays
    Tube current: 40 mA
    Tube voltage: 40 Kv
    Sample plate: glass
    X-ray incident angle: 3° and 12°
  • Methods for producing diastereomers A-5 and B-5 of compound 3H will be shown below in Reference Examples.
    • Reference Example 1
  • Figure US20140011995A1-20140109-C00129
    • Step 1
  • Acetic acid (180 mg, 3.00 mmol) was added to a toluene (90 ml) solution of compound A-1 (4.39 g, 9.33 mmol) and (R)-3-aminobutan-1-ol (998 mg, 11.2 mmol), and the mixture was stirred at 50° C. for 90 minutes. The reaction solution was allowed to cool to room temperature and then poured to a saturated aqueous solution of sodium bicarbonate. The organic layer was separated, while the aqueous layer was subjected to extraction three times with ethyl acetate. The combined extracts were washed with saturated saline and then dried over sodium sulfate. The solvent was distilled off to obtain 4.29 g of crude product A-2.
    • Step 2
  • The crude product A-2 obtained in the preceding step was dissolved in ethanol (40 ml). To the solution, a 2 N aqueous sodium hydroxide solution (20 ml) was added at room temperature, and the mixture was stirred at the same temperature for 2 hours. The reaction solution was neutralized to pH 7 using a 2 N aqueous hydrochloric acid solution. The solvent was directly distilled off. The obtained crude product A-3 was subjected to azeotropy with toluene (100 ml) and used in the next step without being purified.
    • Step 3
  • HOBt (1.65 g, 12.2 mmol) and WSC HCl (2.34 g, 122 mmol) were added at room temperature to a DMF (100 ml) solution of the crude product A-3 obtained in the preceding step, and the mixture was stirred at the same temperature for 15 hours. Water was added to the reaction solution, followed by extraction three times with ethyl acetate. The combined extracts were washed with water three times and then dried over sodium sulfate. The solvent was distilled off, and the obtained oil was subjected to silica gel column chromatography for purification. Elution was performed first with n-hexane-ethyl acetate (3:7, v/v) and then with only ethyl acetate. The fraction of interest was concentrated, and the obtained oil was then dissolved in ethyl acetate. The solution was crystallized with diisopropyl ether as a poor solvent. The obtained crystals were collected by filtration and dissolved again in ethyl acetate. The solution was recrystallized to obtain 1.84 g of compound A-4.
  • 1HNMR (CDCl3) δ: 1.49 (3H, d, J=6.6 Hz), 1.88-1.96 (1H, m), 2.13-2.26 (1H, m), 3.90-4.17 (4H, m), 4.42-4.47 (1H, m), 4.63 (2H, d, J=6.0 Hz), 5.12-5.17 (1H, m), 5.17 (1H, d, J=9.9 Hz), 5.33 (1H, d, J=9.9 Hz), 6.77-6.87 (2H, m), 7.27-7.42 (4H, m), 7.59-7.62 (2H, m), 8.35 (1H, s), 10.41 (1H, t, J=5.7 Hz).
    • Step 4
  • The compound A-4 was subjected to the hydroxy deprotection reaction described in Step F of the paragraph [0088] to obtain compound A-5.
  • 1HNMR (DMSO-d6) δ: 1.41 (3H, d, J=6.3 Hz), 1.8-1.92 (1H, m), 1.50-1.75 (1H, m), 4.02-4.09 (3H, m), 4.28-4.34 (1H, m), 4.53 (2H, d, J=5.7 Hz), 4.64 (1H, dd, J=3.9 Hz, 12.6 Hz), 5.45 (1H, dd, J=3.6 Hz, 9.3 Hz), 7.06 (1H, ddd, J=2.7 Hz, 8.4 Hz, 8.4 Hz), 7.20-7.28 (1H, m), 7.35-7.42 (1H, m), 8.43 (1H, s), 10.37 (1H, t, J=6.0 Hz), 12.37 (1H, brs).
    • Reference Example 2
  • Figure US20140011995A1-20140109-C00130
  • Compound A-1 was reacted with (S)-3-aminobutan-1-ol in Step 1. Compound B-5 was obtained in the same way as in Reference Example 1.
  • 1HNMR (DMSO-d6) δ: 1.41 (3H, d, J=6.3 Hz), 1.85-1.92 (1H, m), 1.50-1.75 (1H, m), 4.02-4.09 (3H, m), 4.28-4.34 (1H, m), 4.53 (2H, d, J=5.7 Hz), 4.64 (1H, dd, J=3.9 Hz, 12.6 Hz), 5.45 (1H, dd, J=3.6 Hz, 9.3 Hz), 7.06 (1H, ddd, J=2.7 Hz, 8.4 Hz, 8.4 Hz), 7.20-7.28 (1H, m), 7.35-7.42 (1H, m), 8.43 (1H, s), 10.37 (1H, t, J=6.0 Hz), 12.37 (1H, brs).
    • INDUSTRIAL APPLICABILITY
  • Use of the production method according to the present invention can reduce the number of steps for producing compounds having HIV integrase inhibitory activity from, for example, conventionally required 16 to 11 steps to preferably 8 to 6 steps. Thus, the production method of the present invention is applicable as an efficient industrial production method and as such, has industrial applicability.

Claims (19)

What is claimed is:
1. A method of producing a compound shown by formula (Y1) or formula (Y2) or a salt thereof:
Figure US20140011995A1-20140109-C00131
(wherein Rx is carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E, and substituent E is as defined below)
comprising a step of:
(Step B)
reacting a compound shown by formula (X2):
Figure US20140011995A1-20140109-C00132
(wherein,
R1d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, carbocyclyl lower alkyloxy optionally substituted by substituent E, heterocyclyl lower alkyloxy optionally substituted by substituent E, or —OSi(R1e)3,
R1es are each independently lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
R2d is hydrogen, lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
R3d is hydrogen, lower alkyloxy optionally substituted by substituent E, —N(R3e)2, or —OR3e,
R3es are each independently lower alkyl optionally substituted by substituent E, or two R3es in —N(R3e)2 together with the adjacent nitrogen atom may form a heterocycle, and
a wavy line means E form and/or Z form or a mixture thereof.
Substituent E: halogen, cyano, hydroxyl, carboxy, formyl, amino, oxo, nitro, lower alkyl, halogen, lower alkyl, lower alkyloxy, carbocyclyl optionally substituted by substituent F, heterocyclyl optionally substituted by substituent F, carbocyclyl lower alkyloxy optionally substituted by substituent F, heterocyclyl lower alkyloxy optionally substituted by substituent F, carbocyclyl lower alkylthio optionally substituted by substituent F, heterocyclyl lower alkylthio substituted by substituent F, carbocyclyl lower alkylamino optionally substituted by substituent F, heterocyclyl lower alkylamino optionally substituted by substituent F, carbocyclyloxy optionally substituted by substituent F, heterocyclyloxy optionally substituted by substituent F, carbocyclylcarbonyl optionally substituted by substituent F, heterocyclylcarbonyl optionally substituted by substituent F, carbocyclylaminocarbonyl optionally substituted by substituent F, heterocyclylaminocarbonyl optionally substituted by substituent F, halogen, lower alkyloxy, lower alkyloxy lower alkyl, lower alkyloxy lower alkyloxy, lower alkylcarbonyl, lower alkyloxycarbonyl, lower alkyloxy carbonylamino, lower alkylamino, lower alkylcarbonylamino, lower alkylaminocarbonyl, lower alkylsulfonyl, and lower alkylsulformylamino; Substituent F: halogen, hydroxyl, carboxy, amino, oxo, nitro, lower alkyl, halogen lower alkyl, lower alkyloxy, and amino protecting group)
with a compound shown by formula (V2):
Figure US20140011995A1-20140109-C00133
(wherein,
R4d is lower alkyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or heterocyclyl lower alkyl optionally substituted by substituent E,
R5d is hydrogen, halogen, lower alkyloxy optionally substituted by substituent E, or —O—SO2—R5e,
R5e is lower alkyl optionally substituted by substituent E, carbocyclyl optionally substituted by substituent E, heterocyclyl optionally substituted by substituent E, carbocyclyl lower alkyl optionally substituted by substituent E, or
heterocyclyl lower alkyl substituted by substituent E, and
Substituent E is as defined above)
to obtain a compound shown by formula (X3) or a salt thereof:
Figure US20140011995A1-20140109-C00134
(wherein each symbol is as defined above).
2. A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
Figure US20140011995A1-20140109-C00135
(wherein Rx is as defined in claim 1)
comprising a step of:
(Step C)
reacting a compound shown by formula (X3), or a salt thereof:
Figure US20140011995A1-20140109-C00136
(wherein each symbol is as defined in claim 1).
with a compound shown by formula (V3), or a salt thereof:

[Chemical formula 7]

H2N—R6d  (V3)
(wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E, and substituent E is as defined in claim 1).
to obtain a compound shown by formula (X4), or a salt thereof:
Figure US20140011995A1-20140109-C00137
(wherein R1d, R2d, and R4d are as defined in claim 1 and R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1).
3. A method of producing of a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
Figure US20140011995A1-20140109-C00138
(wherein each symbol is as defined in claim 1)
comprising a step of:
(Step D)
reacting a compound shown by formula (X4), or a salt thereof:
Figure US20140011995A1-20140109-C00139
(wherein R1d, R2d, R4d are as defined in claim 1 and R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1).
with (R)-3-amino-butan-1-ol, or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′):
Figure US20140011995A1-20140109-C00140
(wherein each symbol is as defined in claim 1).
4. A method according to claim 1 comprising a step of:
(Step C)
reacting a compound shown by formula (X3), or a salt thereof:
Figure US20140011995A1-20140109-C00141
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (V3), or a salt thereof:

[Chemical formula 13]

H2N—R6d  (V3)
(wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1)
to obtain a compound shown by formula (X4), or a salt thereof:
Figure US20140011995A1-20140109-C00142
(wherein R1d, R2d, and R4d are as defined in claim 1 and R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1).
5. A method according to claim 4 comprising a step of:
(Step D)
reacting a compound shown by formula (X4), or a salt thereof:
Figure US20140011995A1-20140109-C00143
(wherein R1d, R2d, and R4d are as defined in claim 1 and R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1).
with (R)-3-amino-butan-1-ol, or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
Figure US20140011995A1-20140109-C00144
(wherein each symbol is as defined in claim 1).
6. A method according to claim 3 comprising a step of:
(Step E)
reacting a compound shown by formula (X5) or formula (X5′), or a salt thereof:
Figure US20140011995A1-20140109-C00145
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (V6), or a salt thereof:

[Chemical formula 18]

RX—NH2  (V6)
(wherein Rx is as defined in claim 1)
to obtain a compound shown by formula (X6) or formula (X6′), or a salt thereof:
Figure US20140011995A1-20140109-C00146
(wherein each symbol is as defined in claim 1).
7. A method according to claim 4, wherein Step B and Step C are continuously performed.
8. A method of producing of a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
Figure US20140011995A1-20140109-C00147
(wherein Rx is as defined in claim 1)
comprising a step of:
(Step B′)
reacting a compound shown by formula (X2):
Figure US20140011995A1-20140109-C00148
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (V2):
Figure US20140011995A1-20140109-C00149
(wherein each symbol is as defined in claim 1)
and a compound shown by formula (V2′):

[Chemical formula 23]

NH4+Xd−  (V2′)
(wherein Xd− is a counter anion of ammonium cation)
to obtain a compound shown by formula (X4′), or a salt thereof:
Figure US20140011995A1-20140109-C00150
(wherein each symbol is as defined in claim 1).
9. A method according to claim 8 comprising a step of:
(Step C′)
reacting a compound shown by formula (X4′):
Figure US20140011995A1-20140109-C00151
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (V3′):

[Chemical formula 26]

R6d-Ld  (V3′)
(wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E, and substituent E is as defined in claim 1, Ld is a leaving group)
to obtain a compound shown by formula (X4), or a salt thereof:
Figure US20140011995A1-20140109-C00152
(wherein R1d, R2d, and R4d are as defined in claim 1 and R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1).
10. A method according to claim 9 comprising a step of:
(Step D)
reacting a compound shown by formula (X4):
Figure US20140011995A1-20140109-C00153
(wherein R1d, R2d, and R4d are as defined in claim 1 and R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1).
with (R)-3-amino-butan-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (X5) or formula (X5′), or a salt thereof:
Figure US20140011995A1-20140109-C00154
(wherein each symbol is as defined in claim 1).
11. A method according to claim 10 comprising a step of:
(Step E)
reacting a compound shown by formula (X5) or formula (X5′):
Figure US20140011995A1-20140109-C00155
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (V6), or a salt thereof:

[Chemical formula 31]

RX—NH2  (V6)
(wherein Rx is as defined in claim 1)
to obtain a compound shown by formula (X6) or formula (X6′), or a salt thereof:
Figure US20140011995A1-20140109-C00156
(wherein each symbol is as defined in claim 1).
12. A method according to claim 1, wherein the compound shown by formula (X2) is obtained by reacting a compound shown by formula (X1):
Figure US20140011995A1-20140109-C00157
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (V1):
Figure US20140011995A1-20140109-C00158
(wherein Pd is lower alkyl optionally substituted by substituent E, and R3d and substituent E are as defined in claim 1).
13. A method according to claim 1, wherein the compound shown by formula (X2) is obtained by reacting a compound shown by formula (Z1):
Figure US20140011995A1-20140109-C00159
(wherein each symbol is as defined in claim 1)
with a compound shown by formula (Z2):
Figure US20140011995A1-20140109-C00160
(wherein each symbol is as defined in claim 1).
14. A method according to claim 1, wherein Rx is carbocyclyl lower alkyl optionally substituted by substituent E.
15. A method according to claim 1, wherein Rx is 2,4-difluorobenzyl.
16. A method of producing a compound shown by formula (Y1) or formula (Y2), or a salt thereof:
Figure US20140011995A1-20140109-C00161
(wherein Rx is as defined in claim 1)
comprising steps of:
(Step C″)
reacting a compound shown by formula (W1):
Figure US20140011995A1-20140109-C00162
with a compound shown by formula (V3), or a salt thereof:

[Chemical formula 39]

H2N—R6d  (V3)
(wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1)
to obtain a compound shown by formula (W2), or a salt thereof:
Figure US20140011995A1-20140109-C00163
(wherein R6d is lower alkyl optionally substituted by substituent E, or lower alkenyl optionally substituted by substituent E and substituent E is as defined in claim 1), and
(Step D″)
reacting a compound shown by formula (W2) with (R)-3-amino-burane-1-ol or (S)-2-amino-propan-1-ol to obtain a compound shown by formula (W3) or formula (W4), or a salt thereof:
Figure US20140011995A1-20140109-C00164
(Step F)
reacting a compound shown by formula (W3) or formula (W4) with a halogenating agent to obtain a compound shown by formula (W5) or formula (W6), or a salt thereof;
Figure US20140011995A1-20140109-C00165
(wherein Hal is a halogen atom).
17. A crystal of a compound shown by formula (U1) or a solvate thereof:
Figure US20140011995A1-20140109-C00166
(wherein Me is methyl, and Bn is benzyl)
which has peaks in a powder X-ray diffraction spectrum at diffraction angle (2θ): 11.2°±0.2°, 17.2°±0.2°, 17.7°±0.2°, 20.5°±0.2°, 22.0°±0.2° and 26.1°±0.2°.
18. A crystal of a compound shown by formula (U2) or a solvate thereof:
Figure US20140011995A1-20140109-C00167
(wherein Me is methyl, and Bn is benzyl)
which has peaks in a powder X-ray diffraction spectrum at diffraction angle (2θ): 7.3°±0.2°, 14.4°±0.2°, 16.1°±0.2°, 18.4°±0.2°, 22.3°±0.2° and 23.1°±0.2°.
19. A crystal of a compound shown by formula (U3) or a solvate thereof:
Figure US20140011995A1-20140109-C00168
(wherein Me is methyl, and Bn is benzyl)
which has peaks in a powder X-ray diffraction spectrum at diffraction angle (2θ): 7.2°±0.2°, 16.1°±0.2°, 18.3°±0.2°, 20.6°±0.2°, 22.6°±0.2°, 23.1°±0.2° and 23.7°±0.2°.
US13/814,333 2010-08-05 2011-08-04 Process for Preparing Compound Having HIV Integrase Inhibitory Activity Abandoned US20140011995A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/709,716 US10125146B2 (en) 2010-08-05 2017-09-20 Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
US15/709,701 US10000508B2 (en) 2010-08-05 2017-09-20 Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate
US15/709,742 US9969750B2 (en) 2010-08-05 2017-09-20 Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010175899 2010-08-05
JP2010-175899 2010-08-05
JP2010277713 2010-12-14
JP2010-277713 2010-12-14
PCT/JP2011/067832 WO2012018065A1 (en) 2010-08-05 2011-08-04 Process for preparing compound having hiv integrase inhibitory activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/067832 A-371-Of-International WO2012018065A1 (en) 2010-08-05 2011-08-04 Process for preparing compound having hiv integrase inhibitory activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/518,209 Division US9321789B2 (en) 2010-08-05 2014-10-20 Methods of producing substituted (4R,12AS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-B][1,3]oxazine-9-carboxamides

Publications (1)

Publication Number Publication Date
US20140011995A1 true US20140011995A1 (en) 2014-01-09

Family

ID=45559561

Family Applications (8)

Application Number Title Priority Date Filing Date
US13/814,333 Abandoned US20140011995A1 (en) 2010-08-05 2011-08-04 Process for Preparing Compound Having HIV Integrase Inhibitory Activity
US14/518,209 Active US9321789B2 (en) 2010-08-05 2014-10-20 Methods of producing substituted (4R,12AS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-B][1,3]oxazine-9-carboxamides
US15/072,388 Active US9650394B2 (en) 2010-08-05 2016-03-17 Methods of producing substituted (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides
US15/471,133 Active US9802959B2 (en) 2010-08-05 2017-03-28 Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones
US15/709,728 Active US10125147B2 (en) 2010-08-05 2017-09-20 Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
US15/709,742 Active US9969750B2 (en) 2010-08-05 2017-09-20 Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones
US15/709,716 Active US10125146B2 (en) 2010-08-05 2017-09-20 Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
US15/709,701 Active US10000508B2 (en) 2010-08-05 2017-09-20 Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate

Family Applications After (7)

Application Number Title Priority Date Filing Date
US14/518,209 Active US9321789B2 (en) 2010-08-05 2014-10-20 Methods of producing substituted (4R,12AS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-B][1,3]oxazine-9-carboxamides
US15/072,388 Active US9650394B2 (en) 2010-08-05 2016-03-17 Methods of producing substituted (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides
US15/471,133 Active US9802959B2 (en) 2010-08-05 2017-03-28 Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones
US15/709,728 Active US10125147B2 (en) 2010-08-05 2017-09-20 Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
US15/709,742 Active US9969750B2 (en) 2010-08-05 2017-09-20 Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones
US15/709,716 Active US10125146B2 (en) 2010-08-05 2017-09-20 Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate
US15/709,701 Active US10000508B2 (en) 2010-08-05 2017-09-20 Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate

Country Status (18)

Country Link
US (8) US20140011995A1 (en)
EP (3) EP3456721B1 (en)
JP (1) JP5636054B2 (en)
CN (3) CN106083891B (en)
BR (1) BR112013002461A2 (en)
CY (1) CY1124582T1 (en)
DK (1) DK3456721T3 (en)
ES (3) ES2608377T3 (en)
HR (1) HRP20210748T1 (en)
HU (1) HUE054473T2 (en)
LT (1) LT3456721T (en)
PL (1) PL3456721T3 (en)
PT (3) PT2602260T (en)
RS (1) RS61796B1 (en)
SG (1) SG187683A1 (en)
SI (1) SI3456721T1 (en)
TW (1) TWI510451B (en)
WO (1) WO2012018065A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
WO2016094198A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9458159B2 (en) 2013-07-12 2016-10-04 Gilead Sciences, Inc. Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
WO2017223280A3 (en) * 2016-06-23 2019-04-25 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11154557B2 (en) 2018-10-22 2021-10-26 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101695807B1 (en) 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 Chemical compounds
PT2376453T (en) 2008-12-11 2020-01-14 Shionogi & Co Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
KR101733625B1 (en) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (en) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 Process for pyrone and pyridone derivatives
TWI582097B (en) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 Process for preparing carbamoylpyridone derivatives and intermediates
EP3456721B1 (en) * 2010-08-05 2021-02-24 Shionogi & Co., Ltd Method of producing compounds having hiv integrase inhivitory activity
ES2770050T3 (en) * 2014-01-21 2020-06-30 Laurus Labs Ltd New procedure for the preparation of dolutegravir and its pharmaceutically acceptable salts
WO2015139591A1 (en) * 2014-03-19 2015-09-24 杭州普晒医药科技有限公司 Crystalline form of dolutegravir sodium salt and preparation method therefor
CN104557686A (en) * 2014-12-29 2015-04-29 徐俊烨 Synthesis method for pyridinone compound
EP3045461A1 (en) * 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
PT3394069T (en) * 2015-12-21 2019-08-30 Lupin Ltd Process for the preparation of hiv integrase inhibitors
JOP20190130A1 (en) 2016-12-02 2019-06-02 Merck Sharp & Dohme Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
ZA201803942B (en) * 2017-06-13 2021-05-26 Cipla Ltd Novel processes for preparation of integrase inhibitor
CA3078442A1 (en) 2017-10-06 2019-04-11 Shionogi & Co., Ltd. Stereoselective process for preparing substituted polycyclic pyridone derivatives
CN108101838B (en) * 2017-12-18 2020-10-20 安徽唯诗杨信息科技有限公司 Synthesis method of dolutegravir intermediate and related substance detection method thereof
US11084832B2 (en) 2019-03-22 2021-08-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN110128448A (en) * 2019-05-22 2019-08-16 博诺康源(北京)药业科技有限公司 The synthetic method of diastereoisomer impurity in a kind of Du Lutewei raw material and intermediate
CN110396099A (en) * 2019-05-22 2019-11-01 博诺康源(北京)药业科技有限公司 The synthetic method of diastereoisomer impurity in a kind of Du Lutewei raw material
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN110698473B (en) * 2019-10-08 2020-12-18 浙江大学 Piperazinone-hydroxypyridone-5-carboxyl compound, preparation and application
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
CN111620891B (en) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 Polyteplavir key intermediate solvate polymorph and preparation method and application thereof
JPWO2022107755A1 (en) 2020-11-17 2022-05-27
CN112480007B (en) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 Synthetic method of 1,3-dimethyl-1H-pyrazole-4-carboxylic acid
CA3202957A1 (en) 2021-01-19 2022-07-28 Hang CHU Substituted pyridotriazine compounds and uses thereof
CN115572257A (en) * 2021-06-21 2023-01-06 江西帝劢药业有限公司 Synthesis method of pyridone compound
WO2023175386A2 (en) * 2021-10-08 2023-09-21 Laurus Labs Limited Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769380A (en) 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
JP4436229B2 (en) 2004-10-20 2010-03-24 株式会社沖データ Electronic equipment
US7858788B2 (en) 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
LT3372281T (en) 2005-04-28 2021-12-10 Viiv Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
JP5297105B2 (en) 2008-07-04 2013-09-25 株式会社クボタ Ride type rice transplanter
JP4975690B2 (en) 2008-07-07 2012-07-11 アルファフーズ株式会社 Method for producing retort food
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2448766T3 (en) * 2008-07-25 2014-03-17 Viiv Healthcare Company Dolutegravir prodrugs
JP2010068253A (en) 2008-09-10 2010-03-25 Sony Corp Encryption processing device
JP2010068262A (en) 2008-09-11 2010-03-25 New Japan Radio Co Ltd Electronic volume
JP2010067176A (en) 2008-09-12 2010-03-25 Nec Corp Information processor
KR101663222B1 (en) 2008-12-11 2016-10-06 시오노기세야쿠 가부시키가이샤 Maltol ether processes and intermediates
KR101733625B1 (en) * 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
PT2376453T (en) * 2008-12-11 2020-01-14 Shionogi & Co Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
TWI518084B (en) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 Process for pyrone and pyridone derivatives
TWI582097B (en) * 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 Process for preparing carbamoylpyridone derivatives and intermediates
EP3456721B1 (en) * 2010-08-05 2021-02-24 Shionogi & Co., Ltd Method of producing compounds having hiv integrase inhivitory activity

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11548901B2 (en) 2012-12-21 2023-01-10 Gilead Sciences, Inc. Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
US10689399B2 (en) 2012-12-21 2020-06-23 Gilead Sciences, Inc. Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
US10035809B2 (en) 2012-12-21 2018-07-31 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
US9732092B2 (en) 2012-12-21 2017-08-15 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
US9663528B2 (en) 2012-12-21 2017-05-30 Gilead Sciences, Inc. Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US11213523B2 (en) 2013-07-12 2022-01-04 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US11883397B2 (en) 2013-07-12 2024-01-30 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US9700554B2 (en) 2013-07-12 2017-07-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US9458159B2 (en) 2013-07-12 2016-10-04 Gilead Sciences, Inc. Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections
US10668064B2 (en) 2013-07-12 2020-06-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US10098886B2 (en) 2014-06-20 2018-10-16 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide
US11202780B2 (en) 2014-06-20 2021-12-21 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10385067B2 (en) 2014-06-20 2019-08-20 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10150780B2 (en) 2014-12-09 2018-12-11 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as HIV integrase inhibitors
WO2016094198A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
US9795602B2 (en) 2014-12-23 2017-10-24 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US10646486B2 (en) 2014-12-23 2020-05-12 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017223280A3 (en) * 2016-06-23 2019-04-25 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
US11117904B2 (en) 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
US11166957B2 (en) 2018-10-22 2021-11-09 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
US11311547B2 (en) 2018-10-22 2022-04-26 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
US11154557B2 (en) 2018-10-22 2021-10-26 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof

Also Published As

Publication number Publication date
PT3456721T (en) 2021-05-04
CN106046022B (en) 2018-06-19
TWI510451B (en) 2015-12-01
SI3456721T1 (en) 2021-05-31
EP3127908A3 (en) 2017-02-15
SG187683A1 (en) 2013-03-28
US20180037593A1 (en) 2018-02-08
JPWO2012018065A1 (en) 2013-10-03
TW201210990A (en) 2012-03-16
CN106083891A (en) 2016-11-09
EP2602260A1 (en) 2013-06-12
EP2602260A4 (en) 2014-01-01
US20180037592A1 (en) 2018-02-08
US20170240564A1 (en) 2017-08-24
PT3127908T (en) 2019-02-04
US20180044351A1 (en) 2018-02-15
US20160229870A1 (en) 2016-08-11
US10125147B2 (en) 2018-11-13
US9802959B2 (en) 2017-10-31
US9969750B2 (en) 2018-05-15
DK3456721T3 (en) 2021-04-26
EP3127908A2 (en) 2017-02-08
EP2602260B1 (en) 2016-09-28
PT2602260T (en) 2016-12-27
LT3456721T (en) 2021-07-12
WO2012018065A1 (en) 2012-02-09
EP3456721A2 (en) 2019-03-20
CY1124582T1 (en) 2022-07-22
US10000508B2 (en) 2018-06-19
EP3127908B1 (en) 2018-11-28
CN103154004A (en) 2013-06-12
ES2608377T3 (en) 2017-04-10
EP3456721B1 (en) 2021-02-24
US10125146B2 (en) 2018-11-13
CN106046022A (en) 2016-10-26
US20180037591A1 (en) 2018-02-08
EP3456721A3 (en) 2019-03-27
ES2870006T3 (en) 2021-10-26
HRP20210748T1 (en) 2021-06-25
US9650394B2 (en) 2017-05-16
US20150038702A1 (en) 2015-02-05
ES2710609T3 (en) 2019-04-26
PL3456721T3 (en) 2021-10-25
CN106083891B (en) 2018-03-23
JP5636054B2 (en) 2014-12-03
HUE054473T2 (en) 2021-09-28
CN103154004B (en) 2016-07-06
BR112013002461A2 (en) 2016-05-24
US9321789B2 (en) 2016-04-26
RS61796B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
US9969750B2 (en) Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones
US9260453B2 (en) Method for producing pyrone and pyridone derivatives
US20230103791A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
CA2756099A1 (en) Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
US20240083896A1 (en) Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
JP2008540630A (en) Novel heterocyclic derivatives
WO2022250104A1 (en) Quinolone derivative having antimalarial activity

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHINOGI & CO., LTD, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUMINO, YUKIHITO;OKAMOTO, KAZUYA;MASUI, MORIYASU;AND OTHERS;REEL/FRAME:030427/0986

Effective date: 20110804

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION